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The goal of transplantation is to implant healthy tissues or organs to successfully replace
those that are damaged or defective. Currently allo-transplantation is almost universally
prevented

by

immune

mediated

rejection

without

significant

pharmacological

intervention. Traditional methods of immune-suppression expose patients to undesirable
risks and side effects, clearly necessitating more specific treatments that will mitigate
immune responses to major and minor histocompatibility mismatches between the
donors and hosts as well as concurrent inflammatory processes. Clinical trials of
biologics targeting T and B cell pathways are ongoing; however, these agents often
require combined treatments with other pharmacologics and still cause various adverse
events. The alternate approach of establishing immune chimerism by concurrent donorderived hematopoietic cell infusion is promising, but requires a period of induction
chemotherapy and has not been successful in some patients. Overexpression of cell
surface molecules such as CD200 or CTLA-4 and PD-1 have also been shown to
promote donor-specific immune tolerance, but these studies are still early in
development. Here, we introduce a novel immune regulator, CD13. Exclusive modulation
of CD13 enhanced survival of minor histocompatibility mismatched skin allografts as well
as growth of embryonic stem cell-derived teratomas in wild type and CD13 null
transgenic mice. Importantly, teratoma growth was identical in immunocompromised
mice, implicating an immune mechanism underlying this phenomenon. While absence of
CD13 in both grafts and hosts provided optimum results, lack of CD13 in graft tissue
alone prevented rejection indefinitely (>100 days). Accepted allografts were associated
with increased mast cell numbers but reduced mast cell degranulation, decreased CD8+
cytotoxic T cells and additional significant differences in immune cell profiles in the grafts
as well as draining lymph nodes. Transient CD13 blockade in wild-type recipients with a
CD13-specific monoclonal antibody also prolonged graft survival. Thus, targeting CD13
may provide an alternate or adjunct therapy to promote transplant survival.
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Chapter 1

Introduction to CD13, Transplant Immunology,
and
Regenerative Medicine

1

1.1 Regenerative Medicine
Regenerative medicine holds the distinct potential of curing virtually all disease
and trauma known to man [1]. This capability stems from the innate inability of
most human organs to fully regenerate after injury and is driven by the integration
of several disciplines including cell biology, immunology, bioengineering,
molecular biology and transplantation medicine [2, 3]. Broadly speaking, the field
can be divided into three categories: cell-based therapies, genetic/biomolecular
therapies, and direct manipulation of endogenous reparative mechanisms. These
genres encompass many different and exciting technologies, which also
synergize to form much more powerful hybrid therapies for conditions that cannot
be cured using only one modality [4, 5]. While endogenous mechanisms of repair
and genetic/biomolecular therapies are very new and promising areas of
research, the following segment will elaborate on cell-based therapies because of
the direct potential application of this project to this branch of medicine.
Afterwards, an overview of transplantation and immunity will set the stage for the
problem this project will address. Finally, a brief synopsis of CD13 will provide the
rationale for choosing this molecule to study.

Cell-based Therapies
The transfer of cells from one living body to another was first recorded as blood
transfusions done between animals in the 1600s, but cell therapy as it is known
2

today was born out of a medical emergency in 1931 when Dr. Paul Niehans
transplanted animal parathyroid tissue to replace the damaged parathyroid of his
patient [6, 7]. Since those early days of crude procedures often practiced on the
scientists themselves, cytotherapy has been become much more regulated to
ensure the safety and quality of the transplants that are being developed to
enhance, replace or repair function of existing or damaged organs [8, 9]. Over
several decades, the repertoire of cells has grown to include not only organspecific cells, such as red blood cells (RBCs) or platelets, but also adult and
pluripotent stem cells (PSCs) [8].

Current classification segregates the available cell types into 4 main categories:
autologous lineage-committed cells, autologous stem cells, allogeneic lineagecommitted cells, and allogeneic stem cells. The stem cell category further
subdivides into tissue-specific adult stem cells and pluripotent stem cells based
on potency [8, 10]. Specifically, PSCs have the capability of generating all of the
cell types in the body and will be described further in later chapters, while adult
stem cells are limited to fewer differentiated cell types. The designation of
autologous or allogeneic is determined by the donor origin of the cells:
autologous cells are collected from and given to the same person while
allogeneic cells are collected from one person and given to another. Each cell
type has advantages and disadvantages, but all are actively being pursued.
3

Bone Marrow Derived Mesenchymal Stem Cell Therapy: Providing a Model
for the Development of Other Cell Therapies
The most extensively characterized cell type being used for therapy is autologous
bone marrow derived mesenchymal stem cells (BMMSCs). The stromal
compartment of the bone marrow harbors multipotent mesenchymal stem cells
(MSCs), which, under appropriate conditions, differentiate into osteoblasts,
chondrocytes and adipocytes [11]. It has also been suggested that MSCs may
also differentiate into cardiomyocytes in vitro and in vivo [12-14], leading to their
use in acute and chronic myocardial infarction models; however, subsequent
studies were conflicting in terms of their differentiation capacity and engraftment
potential [15-17]. Today, MSCs are generally considered to exert their effects
mainly by paracrine mechanisms [18-20]. The MSC-derived paracrine mediators
include pro-angiogenic cytokines and growth factors (such as vascular
endothelial growth factor (VEGF) and angiopoietin 1 (Ang1)) [21] as well as antiinflammatory cytokines (such as PGE2, TGFβ, IL-10 and IL-4) which help
mitigate donor immune-mediated destruction of remaining cardiac cells and the
infused MSCs themselves [22, 23]. Furthermore, MSCs express MHC class I but
not class II molecules or Fas ligand and other co-stimulatory molecules, which
together seem promote a certain degree of immunological tolerance [24].
Altogether, these findings suggest that MSCs create a microenvironment
conducive to healing.
4

Emerging from the success in animal models, BMMSC are currently being
investigated in phase I and II clinical trials for a variety of diseases [25-27].
Preliminary endpoints have unanimously demonstrated the safety of using these
cells, but quantification and validation of efficacy has been more difficult. Indeed,
in the heart, of the several clinical trials have defined the safety of using bone
marrow derived cells (BMDCs), only some have reported improvements in left
ventricular function. For instance, the LateTIME and FOCUS-CCTRN trials found
no differences in outcome of treated versus untreated patients while the RepairAMI trial reported significant increases in ejection fraction [28-30]. Similarly, the
BOOST trial also showed improvement in ejection fraction after intracoronary
infusion of BMDCs [31]. A double-blind, randomized, placebo controlled trial of 32
patients who received unfractionated bone marrow within 24 hours of acute
myocardial infarction also showed smaller infarct area by MRI when compared to
placebo-infused controls [32]. These mixed reports on clinical performance may
be a consequence of the lack of consistency between study protocols and the
inherent variability in cells and patients, all of which complicate the interpretation
of absolute clinical benefits.

Variations in the number and cell types making up the BMDCs, the condition of
the patient when the cells are injected, and the timeframe and method in which
the therapy is administered all seem to affect patient outcome. For instance, in
5

the heart, various methods of cell administration consist of intracoronary,
intravenous, transendocardial, transcoronary sinus, and intramyocardial injection
as well as application of an epicardial patch comprised of cells on a scaffold [33].
Chen et al. administered by intracoronary injection 48-60 billion BMMSCs into 34
patients and reported a 14% higher ejection fraction compared to placebo-treated
controls [34]. These patients exhibited a 10% improvement between 3-6 months
after treatment. More recently, the POSEIDON and PROMETHEUS trials have
utilized a transendocardial or intramyocardial method of delivering MSCs directly
to sites of injury [35, 36]. The POSEIDON trial tested the ability of autologous and
allogeneic MSCs to promote cardiac recovery following transendocardial stem
cell injection (TESI). Using multidetector computed tomography (MDCT) and
biplane left ventriculography, this study reports scar size reductions of
approximately 44% in treated groups versus only 25% in untreated groups with
the greatest improvement seen in those who received 20 million autologous
MSCs. Furthermore, MSC-treated myocardial segments demonstrated greater
than 40% improvement in segmental ejection fraction whereas no improvement
was detected in untreated segments. The smaller PROMETHEUS trial injected
autologous MSCs into akinetic or hypokinetic areas of the hearts that were
unsuitable for surgical revascularization during CABG in 6 patients. Cardiac MRI
analysis demonstrated increased ejection fraction as well as scar reduction and
contractile improvement in areas that received MSC injection over those areas
6

that were surgically reperfused [35]. Notably, this trial reports that patients who
received higher cell doses had reduced scar size. While the lack of a placebo
control group and the very small number of recruited patients prevent the
establishment of definitive improvement with this treatment, PROMETHEUS
seems to argue for greater numbers of MSCs injected directly into nonrevascularized myocardium.

Cumulatively, current clinical trials demonstrate the safety and herald the
potential success of using BMMSCs for cell therapy. A meta-analysis of the 16
largest randomized controlled studies shows variable decreases in infarct size
and an average increase in left ventricular ejection fraction of 11.3% [33]. Overall,
the percent survival of patients receiving BMDCs, calculated at 96% as opposed
to control patients at 84%, was much higher five years after receiving stem cell
intervention. Another critical finding was the fact that MSC therapy worked
equally for infarcts greater than eight years old and recent infarcts between 7-14
days, indicating that immediate treatment may not be necessary. This
observation is important in light of the fact that many patients who just suffered a
heart attack may be too unstable to undergo an invasive procedure immediately.
Furthermore, each additional study continuously refines the therapeutic
population being administered by identification of markers for MSCs, such as
positivity for CD13, CD90 and CD105 and negativity for CD34, CD45 and CD14,
7

as well as the development of better isolation procedures [17]. More specific
definitions of cell types and the use of more predictive surrogate endpoints of
long-term cardiac function are further helping to realize the therapeutic potential
of these cells in the clinic [17]. Such ongoing analysis and re-analysis of
accumulating data is critical to shape a safe and effective cell-based therapeutic
for human use.

Challenges to the realization of successful stem cell therapies
Following the evolution of MSC therapy from preclinical animal models to phase I
and II clinical trials helps to identify common difficulties preventing translation of
other cell therapies. As described in the definition of MSCs, identifying a specific
cell type requires the joint efforts of several groups studying various proteins to
collaboratively form a panel of cell surface markers that exclusively describe that
cell [17, 37]. While many current therapies still rely on broad characteristics and
heterogenous cell populations, continuous refinement of markers will eventually
determine the ideal cell type for a specific condition. Delineating the particular cell
type or types being administered is especially important when using derivatives
of pluripotent stem cells as contamination with residual pluripotent cells may lead
to teratoma formation or stimulation of immune rejection due to ectopic
expression of proteins [18, 38, 39]. In addition to enumerating the cell type(s) for
treatment, formulating the optimal dosage and deciding the best method of
8

delivery is necessary but complicated by the fact that animal models often cannot
correlate to the human body.

Furthermore, to accommodate larger body size, potential loss from technical
challenges and destruction by host immune rejection or disease, sufficient
quantities of cells must be obtained. For tissue-specific cells, proliferation is
limited, requiring either long periods of time in culture or larger harvests from
donors, but do not exhibit any risk of tumor formation. Cell expansion is not
restricted in pluripotent stem cells; however, tumorigenicity of residual pluripotent
cells is a concern. Thus, the adequate production of enough viable product to
deliver to patients is a component to consider when choosing the operative cell
type for therapy.

One of the toughest hurdles to overcome is the host immune system, which
normally prevents graft survival [9, 40, 41]. While immunogenicity is not a
problem for autologous cell therapies, potential rejection is a significant barrier for
allogeneic transplants [42]. Indeed, clinicians and immunologists have studied
the immune sequelae of allo-transplantation for years. To date, they have
identified the cell types and mechanisms involved in rejection and continue to
develop more sophisticated strategies to minimize or prevent such events from
occurring. While much progress has been made, further research is needed
9

before allogeneic cell therapy can finally become a mainstay of medical practice.

1.2 Transplantation and Immunogenicity
Overview of Transplant Medicine
Transplantation medicine is critical in treating a variety of acute and chronic
trauma. Indeed, skin grafts are used for the approximate 450,000 burn injuries
that require professional attention in the USA every year while numerous other
injuries and autoimmune conditions also benefit from the transplant of organs
and tissues [43-46]. Unfortunately, these life-saving procedures are hampered by
insufficient quantity of donor tissue, as well as dismal long-term graft survival
rates, which can be as low as 48% 5 years after pancreatic transplant [47].
These limitations on successful transplant therapy can be directly attributed to
acute or chronic graft rejection as well as Graft Versus Host Disease (GVHD)
[40]. While general immunosuppression helps mitigate some of these
complications, immunosuppression itself exposes patients to a number of harmful
sequelae or, in the case of skin grafts, does not work at all [48, 49]. Thus,
elucidating the pathways that culminate in graft rejection is paramount to
developing more specific therapies that prolong graft function while circumventing
deleterious side effects [40, 50].

10

Mechanisms of Rejection
The immune system consists of two distinct, but communicating branches: the
innate and adaptive responses. Both networks implement multiple methods of
dealing with pathogens, damage or foreign tissue through the use of cells,
antibodies and complement factors. While humoral and complement mediated
immunity have been found to aggravate and, in some cases, drive inflammation,
cell-mediated cytotoxicity is the ultimate executor of rejection [51, 52].

The innate immune system reacts immediately but non-specifically to tissue
injury or infection. Granulocytes, such as neutrophils and mast cells, as well as
macrophages express pattern recognition receptors (PRRs), which bind
pathogen associated molecular patterns (PAMPs) or damage associated
molecular patterns (DAMPs) that are released in the body during pathology. The
toll-like family of receptors (TLRs) is one of the most extensively characterized
PRRs and consists of 13 different cell surface and intracellular proteins that
recognize many different ligands [53]. With regard to transplant immunology,
TLRs 2, 3, 4, and 9 recognize intracellular and extracellular inflammatory signals
including HMGB1, heat shock proteins, and hyaluronan [54-58]. PAMP or DAMP
binding to PRRs stimulate granulocytes and macrophages leading to release of
pro-inflammatory

cytokines

and

chemokines,

upregulation

of

adhesion

molecules, and enhanced antigen presentation in antigen presenting cells
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(APCs) [59]. Activation of APCs such as macrophages and dendritic cells (DCs)
leads to antigen specific T-cell stimulation, thus, allowing the innate immune
system to influence adaptive immune consequences.

Three major pathways govern the adaptive immune response to transplants: the
direct, indirect, and semidirect networks [40, 48]. All of these routes involve
dendritic cell-mediated antigen presentation to T cells; however, the difference
between the direct and indirect is the source of the APC [60, 61]. The direct
mechanism is defined by the presentation of antigen on intact donor major
histocompatibility complexes (MHCs) by donor DCs whereas the indirect pathway
utilizes recipient DCs that have internalized and processed donor antigen on
recipient MHCs [40]. The third semidirect pathway has been implicated in both
stimulation and suppression of the immunity, but is still debated in terms of its in
vivo relevance [48, 62-64]. The semidirect presentation of antigens is believed to
occur through plasma membrane exchanges via trogocytosis or exosomes
between DCs and T cells [48, 65-67]. The direct and indirect, and possibly the
semidirect, pathways of allostimulation culminate in the activation of donorreactive CD4 and CD8 positive T cells and invariably leads to allograft rejection.
Thus, practices that delay initiation or diminish the severity of innate and adaptive
immune responses are imperative to promoting long-term transplant survival and
function.
12

Finding Suitable Donor Tissues and Organs
The most widely used method to mitigate immune-mediated rejection of allografts
involves extensive human leukocyte antigen (HLA) and non-HLA matching of
donors and recipients. In humans, MHCs are termed HLA molecules, which
consist of the Class I HLA-A, -B, and –C as well as the Class II HLA-DP, -DQ,
and-DR proteins [68]. The extent to which these molecules differ between donor
and recipient are directly proportional to the risk of acute and chronic transplant
rejection and typical protocol matches HLA-A, -B, and –DR, but are being
expanded to include HLA-C, -DP and –DQ [9]. In addition, ABO blood group
antigens,

which

could

cause

hyperacute

rejection,

are

analyzed

and

desensitization protocols to remove hemagglutinin A or B from recipient
circulation are performed if necessary. Minor histocompatibility antigens, such as
the H-Y antigen found on the Y chromosome or MHC class 1 related chain A and
B (MICA MICB) are also typed before transplant [69, 70]. The degree to which
recipients are already sensitized to donor antigens is recorded as the percent
panel reactive antibody (PRA) which can be detected by Elisa or Luminex assays
as well as flow cytometry [9]. Higher PRA values indicate greater presence of
pre-existing donor-specific antibodies in the serum of potential recipients,
requiring many immunological parameters to be matched before a suitable donor
is identified.
13

Such immune constraints reduce the already scarce pool of donor organs.
Methods to safely reduce rejection and increase potential sources of donors are
critical to improving patient quality of life. Identification of factors that exclusively
abrogate donor-specific immunogenicity or promote donor-specific tolerance is
an exciting avenue of research that may facilitate this process.

1.3 Introduction to CD13
Structure, Function, and Expression in Tissues
CD13 (also known as aminopeptidase N (APN) or glycoprotein 150 (gp150)) is a
type two transmembrane metalloprotease composed of 7 subunits: a short
intracellular domain, a transmembrane domain and a large extracellular domain
containing the catalytic subunit (Figure 1.1) [71]. CD13 resides on the cell surface
as monomers or dimers and is also found in soluble form in the blood [72, 73]. It
has even been found in exosomes released by microglia in the brain [74].
Recently, x-ray crystallographic analysis of CD13 alone and in association with
known substrates as well as inhibitors has delineated open and closed
monomeric and dimeric structures in addition to identifying an eight-peptide
residue loop that seems to alter conformation, providing substrate-specificity,
which may contribute to this protein’s numerous distinct activities [75].

Found in virtually every organ in the body, CD13 is expressed by a number of
14

different cell types including fibroblasts, activated endothelial cells, epithelial
cells, and myeloid cells [71]. Through enzyme dependent and independent
mechanisms, CD13 influences many different cellular activities including
adhesion, migration, antigen presentation, differentiation, and endocytosis [7679]. The catalytic domain has a preference for N-terminal neutral amino acid
residues and controls the processing of peptide hormones regulating
homeostasis, neuropeptides that control pain, and chemokines involved in
inflammation and angiogenesis [80-82]. Specifically, it is known to cleave
angiotensin III to generate angiotensin IV as well as trim antigenic peptides in the
context of MHC class II molecules [76]. Enzyme independent roles in include
endocytosis, signal transduction and virus recognition [79, 83-85].

Given the distribution of CD13 in myeloid cells, epithelial cells, and inflammatory
endothelium, CD13 has been speculated to influence the balance between pro
and anti-inflammatory events in a variety of conditions such as autoimmunity,
ischemic injury, infection and cancer [78, 86-91]. To clarify the numerous
functions attributed to CD13 in these disorders, our lab has generated and
extensively characterized a global CD13 null transgenic mouse [92]. Deletion of
exons four through 13 of the 20 exon coding region of CD13, eliminated the
catalytic domain as well as most of the extracellular subunits in the CD13 null
mouse which could be confirmed by PCR and various methods of
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immunodetection in tissues that normally express CD13. Such transgenic mice
have enabled investigators to analyze the physiological relevance of CD13
innormal development and homeostasis, such as in gestational mammary gland
morphogenesis

and

adult

mammary

gland

remodeling,

in

addition

to

contributions to pathophysiology, seen in various tumor and injury models [78,
79, 91, 93].

Interestingly, while these CD13 null mice showed no overt anomalies
developmentally, various animal models of injury have elucidated specific
differences in inflammatory responses compared to WT counterparts. For
instance, tumor allograft models in WT and CD13 null mice have shown the
importance of CD13 expression on cancer cells as well as stromal cells in the
microenvironment for optimal tumor growth and metastasis [91]. Myocardial
infarction and hind-limb ischemia models have demonstrated the importance of
CD13 in promoting inflammation, as absence seemed to favor an antiinflammatory milieu [78, 90]. Indeed, emerging evidence implicates CD13 as an
enhancer of inflammation by promoting potentially damaging inflammatory
monocyte trafficking and exacerbating the innate and adaptive immune
responses, while also playing a key role in tissue repair by promoting the
maintenance and renewal of resident stem cells [77, 94]. Additionally, in
response to tissue injury, CD13 impacts the generation of reactive oxygen
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species through interferon signaling in an iNOS-dependent manner [95]. In
conjunction with its signaling effects, CD13 has also been demonstrated as a
negative regulator of receptor-mediated, dynamin-dependent endocytosis in
fibroblasts and dendritic cells as well as phagocytosis in myeloid cells [95].
Cumulatively, these findings form a body of evidence that is slowly clarifying the
molecular mechanisms responsible for the wide scope of activities of this
versatile protein.

1.4 Goals of This Study
Recent findings describing the creation of an anti-inflammatory microenvironment
in certain injury models where CD13 is absent suggest that CD13 may be a
suitable target to mitigate acute inflammatory events leading to rejection of
allografts. Accordingly, this study uses WT and global CD13 null mice in two
specific allotransplant models: the skin graft model and the teratoma formation
assay. Prolonged survival of allografts in the absence or specific blockade of
CD13 supports our hypothesis that CD13 modulates transplant immunity.
Furthermore, cellular findings, in line with published results from other groups
identifying mast cells as critical regulators of allograft tolerance, may suggest a
CD13-dependent mast cell mediated mechanism. Cumulatively, this project
describes the outcome of allografts lacking CD13 and serves as the initial step
towards developing a CD13-based cell therapy in the future.
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1.5 Figures and Legends
FIGURE 1.1 – CD13 PROTEIN STRUCTURE
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Figure 1.1 CD13 Protein Structure.
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Chapter 2

Materials and Methods
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Mice
Global CD13 null mice in the C57Bl/6 and FVB backgrounds were generated by
the Gene Targeting and Transgenic Facility (GTTF) at the University of
Connecticut Health Center (UCHC) and extensively characterized by previous
members of the lab. Specifically, exons 4-13 of the CD13 gene on chromosome 7
were deleted and the complete absence of gene expression in all appropriate
tissues and organs was substantiated by PCR (Table 2.1), RT-PCR, western blot
analysis and immunostaining. Wild type (WT) and CD13 null mice were bred and
genotyped before use at 4-10 weeks of age [92]. NIHS-LystbgFoxn1nuBtkxid mice
were purchased from Harlan Laboratories (South Easton, MA) and used at 6
weeks of age. All experiments with mice were carried out according to guidelines
and following protocols approved by the Animal Care Committee (ACC) of the
Center for Comparative Medicine (CCM) at the University of Connecticut Health
Center.

Cells and Cell Culture
WT and CD13 null mouse embryonic stem cells (mESCs) were derived by the
GTTF at UCHC using WT and CD13 null C57Bl/6. Eleven mES lines were
generated and genotyped according to a previously established protocol [92].
Three individual WT and CD13 null mES lines were used for subsequent studies
(two male lines and one female line per genotype). These lines were either
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cultured on mitomycin C-inactivated MEF in knock-out Dulbecco’s Modified Eagle
Medium (KO-DMEM) (Life Technologies, Grand Island, NY) containing 15%
knock-out serum replacement (KOSR) (Life Technologies), 1% penicillin (100
units/ml)-streptomycin (100 units/ml) (P/S) (Life Technologies), 1% non-essential
amino acids (NEAA) (Life Technologies), 1% L-glutamine (Life Technologies) and
55μM β-mercaptoethanol (Sigma, St. Louis, MO) or feeder-free on a 0.1% gelatin
matrix (Sigma) in the same media supplemented with 2% conditioned medium
from Chinese Hamster Ovary (CHO) cells producing leukemia inhibitory factor
(LIF) (generously provided by Dr. Christine Finck from the University of
Connecticut Health Center, Farmington, CT). All ES lines were cultured in 5%
CO2 at 37°C. For embryoid body formation, 1000 ES cells were plated in 25μl of
media without LIF in hanging drops for seven days before transfer to regular
culture [96]. Pluripotency of these lines was confirmed by immunostaining for
pluripotency markers OCT4 (R&D Systems, Minneapolis, MN) and NANOG
(Abcam, Cambridge, MA) as well as assessing embryoid body and teratoma
formation.

Mast cells were derived from 6-10 week old male and female C57Bl/6 or FVB WT
and CD13 null mice according to well-established protocols [97]. Briefly, femurs
and tibias were harvested with sterile surgical instruments and cut at the
epiphyseal lines to expose the medullary cavities. Bone marrow was flushed out
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using 5ml syringes containing DMEM supplemented with 10% fetal bovine serum
(FBS) (GE Healthcare, Logan, UT), 2mM L-glutamine (Life Technologies), 1%
P/S (Life Technologies) and 50μM β-mercaptoethanol (Sigma). Cells were
pelleted by centrifugation at 500 x g for 5 minutes at room temperature. Cell
pellets were resuspended in the same medium as above with the addition of 10
ng/ml of interleukin-3 (IL-3) (Peprotech, Rocky Hill, NJ) and plated in T75 flasks
at a density of one T75 flask per mouse. The next day, cells in suspension were
collected and transferred to new flasks in fresh media containing IL-3. Cultures
were subsequently fed every 3 days with fresh media for 4-8 weeks to allow for
mast cells to mature. All primary mast cell lines were cultured in 5% CO2 at 37°C.
Generation of mature mast cells was confirmed with flow cytometry for the
expression of c-Kit (Biolegend, San Diego, CA) and FcεR1 (eBioscience, San
Diego, CA) as well as toluidine blue (Sigma) staining for metachromatic granules.

Primary dermal fibroblast (DF) cultures were generated from male C57Bl/6 and
FVB WT and CD13 null mice. Mice were euthanized by CO2 narcosis and
cervical dislocation before shaving and sterilizing a 20 mm by 20 mm area of the
dorsum. This 20 x 20 mm2 full-thickness piece of skin was harvested and minced
into smaller pieces using sterile surgical scissors before enzymatic dissociation in
a buffer containing 0.05% Trypsin (Life Technologies) and 5 mg/ml Collagenase
A (Sigma) for 10 minutes at 37°C, agitating them once at 5 minutes. Enzymatic
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digestion was stopped with the addition of DMEM (Life Technologies) containing
10% FBS (GE Healthcare) and 1% P/S (Life Technologies) and centrifuged at
1200 rpm for 5 minutes at room temperature. Digests were washed twice with
phosphate buffered saline (PBS) (Life Technologies) before plating in 1 gelatincoated T75 flask per mouse in 5ml of media to allow for larger pieces of skin to
adhere to the flask overnight. Alternatively, digests from 2 mice were collectively
plated in 8ml of media in 1 gelatin-coated T175 overnight. The next day, media
was gently aspirated to prevent detachment of skin from the flask and fresh
media was added just as carefully. By one week, cells grew out from the larger
pieces of skin that adhered to the flasks. These cultures were then passaged 1:1
to evenly distribute the cells. Thereafter, cells were allowed to reach 70%
confluency before passaging 1:2. All fibroblast lines were cultured in 5% CO2 at
37°C and used between passages 4 and 6. Fibroblast cultures were confirmed
by immunostaining for expression of Vimentin (Cell Signaling Technologies,
Danvers, MA) but not of CD31 (BD Pharmingen, Franklin Lakes, NJ) or αSmooth
Muscle Actin (αSMA) (Abcam).

Teratoma Formation Assays
Teratomas were generated according to standard published protocols. Briefly,
recipient

WT

and

CD13

null

C57Bl/6

mice

at

ages

6-8

weeks

LystbgFoxn1nuBtkxid mice (Harlan Laboratories) were anesthetized and, if
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or

necessary, shaved on their dorsolateral flanks for easier observation.
Concomitantly, WT and CD13 null mESCs were gently dissociated with 0.05%
trypsin (Life Technologies) from feeder free cultures and processed into single
cell suspensions in a 1:1 mixture of DMEM (Life Technologies) and Matrigel (BD
Biosciences). mESC suspensions were loaded onto 1cc syringes and kept
horizontally on ice with intermittent rotation until use within a few minutes. One
million WT or CD13 null mESCs in a total volume of 100μl were injected
subcutaneously into the right or left dorsolateral flanks respectively through a 25guage needle (Figure 2.1). Mice were observed for 4 to 6 weeks before sacrifice.

MiHC and MHC Mismatched Skin Grafts
Skin transplants were performed according to previously published protocols
(Figure 2.2) [98]. Table 2.2 lists the various combinations of miHC and MHC
mismatch skin transplants. Donor mice were euthanized and the ears were
sterilized with 70% ethanol. Using sterile surgical instruments, both ears were cut
off at the base and the dorsal skin was gently peeled away from the collagenous
ventral flap. Skin grafts were kept in sterile PBS on ice until use within 15
minutes. Anesthetized recipient mice were shaved on their backs and wiped with
70% ethanol before a graft bed was created by removing an 8mm wide, round,
full-thickness piece of skin. Donor skin was gently placed on the graft bed and
any air trapped underneath was pushed out. Overhanging pieces of skin was
25

trimmed off before bandaging the mice around the abdomen. 0.05 mg/g of
buprenorphine was administered to the mice for post-operative pain and mice
were monitored daily for the first week for any signs of distress. After that, mice
were monitored every 3 days until time of sacrifice. Bandages were replaced
every three days under inhaled anesthesia for the first 2 weeks, but permanently
removed thereafter. For long-term graft analysis, diameters of the grafts were
measured and quality of the skin was assessed for 40 to 100 days.

For the in vivo assessment of CD13 inhibition on graft survival, recipient mice
were pre-treated with a CD13 blocking antibody, SL13, for two weeks prior to
skin transplant (Figure 2.3). SL13 is a monoclonal rat antibody produced by
Promab

Biotechnologies

(Richmond,

CA)

against

mouse

CD13

and

characterized by our lab. 200μl of purified SL13 antibody at a concentration of
28ng/μl in sterile PBS was injected every other day into the intraperitoneal cavity
of WT and CD13 null FVB male and female mice at 6 weeks of age. Presence of
circulating SL13 was confirmed by immunocytochemistry using serum drawn
from treated mice versus serum drawn from vehicle control mice and human
C33a cells expressing mouse CD13. After two weeks, skin transplantation was
performed as described above and SL13 treatment was discontinued.
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Mixed Lymphocyte Reactions with Mast Cells
Bone marrow derived mast cells (BMDMC) from WT and CD13 null male C57Bl/6
or FVB mice were used to stimulate CFSE-labeled splenocytes isolated from WT
and CD13 null C57Bl/6 or FVB female mice (Figure 2.4). BMDMCs were treated
with 10μg/ml Mitomycin C (Santa Cruz Biotechnology, Dallas, TX) for 2-3 hours
at 37°C and washed three times with DMEM containing 10% FBS and 1% P/S.
Spleens from 6-10 week old mice were harvested and manually dissociated with
sterile scalpels. Cells were collected and red blood cells (RBCs) were lysed using
RBC lysis buffer (Sigma) for 5 minutes at room temperature. Lysis was stopped
with sterile PBS (Life Technologies) and cells were centrifuged for 5 minutes at
1200rpm at room temperature. Cells were washed twice with PBS and filtered
through a 40μm cell strainer. Cells were counted and resuspended at a
concentration of 1x107 cells/ml in PBS and incubated with CFSE dye (Life
Technologies) at a concentration of 10μM for 10 minutes at room temperature.
Labeled cells were washed three times with 10ml of sterile PBS before counting
again. 250,000 CFSE-labeled splenocytes were co-cultured with 500,000
Mitomycin-inactivated BMDMCs per well in triplicate of a 24-well plate for 6-10
days in DMEM containing 10% FBS and 1% P/S before flow cytometry analysis
for splenocyte proliferation.
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Mast Cell/Dermal Fibroblast Co-cultures
Primary female BMDMCs and male DFs from WT and CD13 null C57Bl/6 or FVB
mice were co-cultured to assess DF-stimulated mast cell proliferation or
degranulation (Figure 2.5). DFs were treated with 10μg/ml Mitomycin C (Santa
Cruz Biotechnology) for 2-3 hours at 37°C and washed three times with DMEM
containing 10% FBS and 1% P/S. BMDMCs were counted and incubated at a
concentration of 1x107 cells/ml in PBS with 10μM CFSE dye (Life Technologies)
for 10 minutes at room temperature. Labeled cells were washed three times with
10ml of sterile PBS before counting again. 250,000 CFSE-labeled BMDMCs were
co-cultured with 500,000 DFs for 2-10 days in DMEM containing 10% FBS and
1% P/S before flow cytometry analysis for MC proliferation. Alternatively, 250,000
unlabeled BMDMCs were co-cultured with 500,000 DFs for 2-10 days in DMEM
containing 10% FBS and 1% P/S for analysis of β-hexosaminidase release.

β-Hexosaminidase Assay
WT and CD13 null BMDMCs were stimulated with either 100ng/ml FcεR1
(eBioscience, San Diego, CA) overnight or coculture with primary DFs as
described in the previous section. Following stimulation, cells were washed with
sterile HEPES buffer (Life Technologies) three times and equilibrated to 37°C for
at least 30 minutes. P-nitrophenyl N-acetyl-β-D-glucosamide (PNAG) (Sigma)
was prepared by sonicating 35mg of PNAG into 10ml of 40mM citrate buffer at
28

pH 4.5. 100μl of PNAG solution was added to each well of a 96-well plate. To
this, 50μl of supernatant from Fc or DF stimulated BMDMCs was added in
replicates of 9. To determine total β-hexosaminidase activity, cells were lysed
with 0.1% Triton X-100 solution (Sigma) and 50μl of the lysate was added to the
100μl of PNAG solution in replicates of 9. Lysates and supernatants were
incubated with PNAG solution for 90 minutes at 37°C without CO2 before adding
50μl 0.4M glycine buffer at pH 10.7 to each well. Resulting plates were read with
the Microplate Reader 550 (BioRad, Hercules, CA) using MPM 1.80 software at
450nm with a reference filter of 655nm. Percent degranulation was calculated
using the following formula:
% release = 100 x (2 x (supernatant - plate blank)) / (0.5 x (supernatant - plate
blank) + (4 x (lysates - plate blank)))

Special Stains
Hematoxylin-Eosin staining was performed on teratoma and skin graft tissue
sections in the Research Histology Core (RHC) according to their guidelines.
Apoptag® staining of teratoma and skin graft tissue sections was outsourced to
the RHC at UCHC. Toluidine blue staining was performed according to previously
established protocols and manufacturer’s recommendations. Toluidine blue
(Sigma) working solution at a concentration of 1mg/ml in 1% sodium chloride
solution at a final pH of 2.0-2.5 was made fresh each time. Tissue sections were
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deparaffinized and rehydrated as above before staining in toluidine blue working
solution for 2-3 minutes. Slides were then washed three times in distilled water
and dehydrated quickly from 95% to 100% alcohol to prevent loss of staining.
Tissue sections were cleared in Xylene (Anapath, Lewisville, TX) and
coverslipped with Cytoseal (Thermo Scientific, Pittsburgh, PA).

MTT Proliferation Assay
mESCs were trypsinized to a single cell suspension and counted. In a 96 well
plate, WT and CD13 null mESCs were plated feeder-free in ESC media
containing LIF at a starting cell number of 8,000 cells per well in triplicate. One
set of wells was measured at regular intervals between days 0 and 12.
Specifically, 20μl of 5mg/ml MTT solution was added to each well and incubated
at 37°C for 4 hours. The supernatant was gently removed and 150μl of MTT
solvent (4mM hydrochloric acid and 0.1%

Nondet P-40 in isopropanol) was

added and triturated to lyse the cells. Absorbance was read using the Microplate
Reader 550 (BioRad) at 595nm with a reference filter of 655nm.

Immunohistochemistry and Immunofluorescence
For histological analysis, skin grafts, the draining lymph nodes and spleens were
harvested and fixed in 10% formalin (Fisher Scientific, Pittsburgh, PA) for 4 hours
and dehydrated in 70% ethanol overnight before submission to the UCHC
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Research Histology Core for paraffin embedding and processing. For BrDU
labeled teratomas, mice were injected in the peritoneal cavity with 100ul of
10mg/ml BrDU (BD) 2 hours before sacrifice. Harvested teratomas were also
fixed in 10% formalin for 4 hours and dehydrated in 70% ethanol overnight before
submission to the Research Histology Core for paraffin embedding and
processing.

Processed tissue sections of 5-8μm were deparaffinized and rehydrated at room
temperature before antigen retrieval with either a Citrate buffer (Sigma) or a
Tris/EDTA buffer (Fisher Scientific) in a steamer. Tissues destined for
immunohistochemical staining were blocked with 3% hydrogen peroxide (Fisher
Scientific) for 15 minutes at room temperature. All tissue sections were subject to
a blocking step with 10% normal serum (Vector Laboratories, Burlington, CA) for
one hour at room temperature. If probing for an intracellular antigen, 0.2% Triton
X-100 (Sigma) in 10% normal serum was used to permeabilize the cells for 30
minutes at room temperature. Tissue sections were then probed with the
appropriate primary antibody in 5% normal serum overnight at 4°C. Primary
antibodies used are: rat anti-OCT4 (R&D), rat anti-CD13 (Shapiro Lab), mouse
anti-BrDU (Millipore), goat anti-CD31 (BD), goat anti-Vimentin (Cell Signaling),
rabbit anti-CD3 (Dako, Carpinteria, CA), rabbit anti-Ki67 (Abcam), rat anti-CD8
(Thermo Scientific), rabbit anti-c-kit (Abcam). The next day, tissue sections were
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washed and probed with the appropriate secondary antibody in 5% normal
serum. The secondary antibodies include: goat anti-rat, goat anti-rabbit, goat
anti-mouse-488 (Vector). Secondary immunofluorescent antibodies include: goat
anti-rat Alexa 488, goat anti-rat PE, goat anti-rabbit Alexa 488, goat anti-mouse
Alexa 488 (all from Life Technologies). Immunohistochemical detection was
completed with a 30 minute room temperature incubation with ABC reagent
(Vector) followed by appropriate incubation at room temperature with Nova Red
(Vector) or DAB (Vector). For nuclear counterstaining, immunofluorescent slides
were

mounted

with

Vectashield

containing

DAPI

(Vector)

while

immunohistochemically processed slides were stained with hematoxylin (Vector),
dehydrated, cleared in Histoclear (National Diagnostics, Atlanta, GA), and
coverslipped with Cytoseal (Thermo Scientific). Images were obtained from a
Zeiss Axioplan 2 microscope with AxioCam MRc software or the ApoTome.2
microscope with AxioVision software (Zeiss, Peabody, MA) and quantified with
ImagePro Plus software (Media Cybernetics, Silver Springs, MD).

Flow Cytometry
For flow cytometric analysis, skin grafts, draining lymph nodes, and spleens were
collected and dissociated into single cell suspensions. The skin was minced into
small

pieces

before

digestion

in

5mg/ml

collagenase

A

(Sigma)

Dispase/DMEM F12 (Stem Cell Technologies) supplemented with 100ng/ml
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in

DNase (Worthington Biochemicals, Lakewood, NJ) using the gentleMACS
dissociator (Miltenyi, Bergisch Gladbach, Germany). Digestion was stopped with
DMEM containing 10% FBS and cells were filtered through 100μM cell strainers
before washing twice and counting. Spleens and lymph nodes were manually
dissociated between two frosted slides and RBCs were lysed with RBC lysis
buffer (Sigma) and filtered through 40μM cell strainer. Cells were then washed in
FACS buffer (PBS with 2% heat inactivated FBS) and counted. Cells were
incubated with fluorescently conjugated primary antibodies (anti-CD45-PE, antiCD3-FITC, anti-CD11b-Pacific Blue (Biolegend), anti-CD8-Pacific Orange, antiCD4-PerCP/Cy5.5, anti-CD11c-PE/Cy7, anti-F4/80-FITC (Biolegend), anti-Ly6CPerCP/Cy5.5, anti-CD206-Alexa 647, anti-CD19-Alexa 700, anti-NK1.1-Alexa
700, anti-Ly6G-Alexa 700, anti-CD3-Alexa 700 (all from eBioscience unless
otherwise noted)) as well as LIVE/DEAD® Fixable Blue (Life Technologies) for 30
minutes on ice. Cells were then washed three times in FACS buffer before
analysis with the LSR II flow cytometer and FACSDiva software (BD). Further
analysis was conducted using Flowjo (Tree Star Inc., Ashland, OR).

Primary BMDMCs were collected from cell cultured and washed three times in
FACS buffer before staining with primary antibodies (armenian hamster antiFcεR1 (eBioscience), biotinylated anti-ckit (Abcam)). Following 3 washes with
FACS buffer, an additional 30 minute incubation with secondary antibodies (goat
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anti-armenian hamster Alexa 488, Streptavidin-Alexa 647 (Life Technologies))
was required for labeling. Labeled cells were then analyzed with the LSR II flow
cytometer and FACSDiva software (BD) with further analysis using Flowjo (Tree
Star Inc., Ashland, OR).

Statistical Analysis
Graphpad Prism software was used to perform an ANOVA test with appropriate
tests for equal variances. Data from individual experiments were represented as
mean ± standard error (SEM) in vivo or mean ± standard deviation for in vitro
assays. Statistical significance was defined and indicated as p ≤ 0.05 (*), p ≤
0.01 (**), p ≤ 0.001 (***).
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2.2 Figures and Legends
TABLE 2.1 – CD13 GENOTYPING PRIMERS
FIGURE 2.1 – TERATOMA FORMATION ASSAY
FIGURE 2.2 – MURINE SKIN ALLOGRAFT MODEL
TABLE 2.2 – MIHC AND MHC MISMATCH GRAFT COMBINATIONS
FIGURE 2.3 – SL13 TREATMENT MODEL
FIGURE 2.4 – MAST CELL/SPLENOCYTE CO-CULTURE ASSAY
FIGURE 2.5 – MAST CELL/DERMAL FIBROBLAST CO-CULTURE ASSAY
TABLE 2.3 – FLOW CYTOMETRY PANEL
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Primer
CD13
Forward (P1)
WT Allele
Reverse (P2)
KO Allele
Reverse (P3)

Sequence
5’-ACCGTGCTCGGTTTCCTCTGTTTA-3’
5’-TGTGGAAAGGATCCCGGTGTCAAT-3’
5’-ATTGTTCTTATGCTGAGTGACAAG-3’

Table 2.1 CD13 Transgenic Mouse Genotyping
Primers.
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4-6 weeks

Figure 2.1 Teratoma Formation Assay.
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Figure 2.2 Murine Skin Allograft Model.
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Donor
WT C57Bl/6 M
WT C57Bl/6 M
KO C57Bl/6 M
KO C57Bl/6 M
miHC
mismatch WT FVB M
WT FVB M
KO FVB M
KO FVB M
WT C57Bl/6 F
WT C57Bl/6 F
KO C57Bl/6 F
KO C57Bl/6 F
MHC
mismatch WT FVB F
WT FVB F
KO FVB F
KO FVB F

Recipient
WT C57Bl/6 F
KO C57Bl/6 F
WT C57Bl/6 F
KO C57Bl/6 F
WT FVB F
KO FVB F
WT FVB F
KO FVB F
WT FVB F
KO FVB F
WT FVB F
KO FVB F
WT C57Bl/6 F
KO C57Bl/6 F
WT C57Bl/6 F
KO C57Bl/6 F

Results
Reject
Reject
Accept
Accept
Reject
Reject
Accept
Accept
Reject
Reject
Reject
Reject
Reject
Reject
Reject
Reject

Table 2.2 Murine Skin Allograft Combinations.
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Figure 2.3 SL13 Treatment Model.
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Figure 2.4
Assay.

Mast

Cell/Splenocyte
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Co-Culture

Figure 2.5 Mast Cell/Dermal Fibroblast Co-Culture
Assay.
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Cell Type
Mast cell
M1
Macrophage
M2
Macrophage
Helper T cell
Cytotoxic T
cell
Dendritic
cell
Monocyte
B cell
Natural
Killer cell

Surface Marker Profile
L/D-CD45+cKit+FcεR1+
L/D-CD45+CD3-CD19-NK1.1CD11b+F4/80loLy6C+CD206L/D-CD45+CD3-CD19-NK1.1CD11b+F4/80hiLy6C-CD206+
L/D-CD45+CD19-CD3+CD4+
L/D-CD45+ CD19-CD3+CD8+
L/D-CD45+CD3-CD19-NK1.1-Ly6GF4/80-CD11b+CD11c+
L/D-CD45+CD3-CD19-NK1.1-Ly6GF4/80-CD11b+CD11cL/D-CD45+CD3-CD19+
L/D-CD45+CD3-NK1.1+

Table 2.3 Flow Cytometry Marker Profile.
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Chapter 3

CD13 Influences Skin Transplant Survival
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3.1 Introduction
Graft rejection is a substantial problem limiting not only the transplants of
cadaveric and living donor organs, but also cell and tissue therapies generated
from other non-autologous sources. Current practices to reduce graft failure
involve extensive HLA and non-HLA-matching and life-long systemic immune
suppression of recipients [9, 99]. While coordinating immune profiles of donors
and recipients is critical for graft survival and patient safety, this process reduces
the already insufficient pool of donor organs suitable for transplantation.

Not surprisingly, over the past decade, the numbers of candidates on transplant
waiting lists for every organ except the pancreas has increased [100]. In fact,
while the number of active candidates on the kidney transplant list has increased
to almost 60,000 subjects, the number of kidney transplant surgeries has actually
decreased by 1.7% between 2011 and 2012, creating a three-fold discrepancy
between the number of patients requiring transplants and the number of
procedures performed [100]. The decrease in number of procedures performed
extends to other organs such as the liver where the decreased transplant rate is
attributed to worsening of the donor shortage. Furthermore, greater than 50% of
pediatric patients receiving deceased donor kidney transplants still succumb to
graft failure from chronic immune rejection after 10 years requiring secondary,
even tertiary transplants despite steady improvements in short and long-term
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graft function achieved by continuous remodeling of induction and maintenance
immunosuppressive practices. Thus, these overall trends overwhelmingly point to
the need for better methods of abrogating immune rejection.

Current guidelines for immunosuppression vary depending on the organ to be
transplanted and the age category of the patient among other variables [101]. In
general, combination therapies consisting of steroids (such as prednisone),
calcineurin inhibitors (CNIs) (such as cyclosporine and tacrolimus), and
antimetabolites

(such

as

azathioprine

and

mycophenylate

mofetil)

are

implemented to mitigate the damaging sequelae of innate and adaptive of
immune reactions [99, 102]. Unfortunately, even when successful in maintaining
graft function, maintenance immunosuppression inflicts many side effects.
Calcineurin inhibitors are notoriously nephrotoxic and can also lead to
hypertension, hyperlipidemia and skin changes. Mycophenylate mofetil has
largely replaced azathioprine due to superior performance and lower risk profile;
however, it too has significant unintended effects on the gastrointestinal and
hematologic systems. Newer additions to the repertoire include T cell depleting
antibodies (such as antithymocyte globulin (ATG) and alemtuzumab), nondepleting antibodies (such as TOL101 and abetacept), the Mammalian Target of
Rapamycin (mTOR) inhibitor (sirolimus), and the Sphingosine-1-Phosphate
(S1P) receptor antagonist (FTY720) [102]. These drugs have expanded the
46

artillery used to combat graft rejection; however with severe complications, such
as bradycardia with FTY720 or hyperlipidemia and impaired wound healing with
sirolimus, and a lack of large-scale studies conclusively demonstrating benefit
over current standard protocol, an ideal pharmacotherapy remains elusive.

In addition to these non-immune complications, general immune suppression
increases morbidity from opportunistic infections and cancers and even fails to
work in certain circumstances, especially in the skin [48]. Thus the over 7 million
people suffering from large chronic cutaneous wounds and burns currently
require the generation of graft tissue from surgical removal of unaffected skin
from a different area of the body, the application of autologous cells (as in
Hyalograft 3D and Laserskin Autograft), or the administration of less
immunogenic fetal allogeneic cells (as in OrCel, Apligraf, and Dermagraft) [43,
103]. The skin is a complex organ consisting of several individual layers that
collectively form two main layers, the epidermis, which is in contact with the
external environment, and the underlying dermis. While the majority of cells in the
epidermis consist of keratinocytes, significant numbers of resident dendritic cells,
called Langerhans cells, constantly sample the external environment to aid the
body’s defenses. Furthermore, the dermis which contains mostly dermal
fibroblasts, cutaneous nerves, and cells making up hair follicles and sebaceous
glands, also host significant numbers of resident immune cells such as mast cells
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and dermal dendritic cells which migrate from the many small blood vessels that
run through this layer. A full-thickness skin graft consists of both dermis and
epidermis as well as all of those cells they contain. Because of its refractory
nature to systemic immunosuppressants, the skin allo-transplantation model is
considered one of the most rigorous tests for proving efficacy of novel immunemodulating therapies in preclinical development [98, 104, 105].

Indeed, several mechanisms that are currently being studied clinically are
concurrently being refined and expanded in animal models of skin transplant.
One successful example of such translational research is the evolution of
establishment

of

donor-specific

tolerance

through

the

generation

of

hematopoietic microchimerism, which supports allograft survival and in many
cases allows discontinuation of immunosuppressive drugs [106]. Clinically, this
process typically uses hematopoietic stem cells with or without other lymphoid or
bone marrow derived cells in combination with induction chemotherapy
perioperatively [107, 108]. In the laboratory, the original heterogeneous
populations of hematopoietic and bone marrow derived cells are being dissected
using rodent skin allotransplants as a readout to determine the actual population
of cells which mediate the establishment of chimerism [109, 110]. Although the
factors favoring generation of macrochimerism are unknown, clinical trials hoping
to capitalize on DC mediated tolerance are currently underway [107, 110-114].
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These trials consist of infusing a donor-derived tolerance-inducing “Facilitating
Cell” (FC) population around the time of transplant surgery. This mixed
population of cells are predominantly CD8+CD11c+CD11b- plasmacytoid DCs,
which seem to enhance in vivo development of CD4+CD25+FoxP3+ Tregs and
enable

donor-specific

immune

tolerance

even

after

the

withdrawal

of

maintenance immunosuppressive therapy [109-111, 115]. While exciting, the
process of inducing chimerism is not trivial, requiring total body irradiation for the
engraftment of donor cells in recipient bone marrow as well as induction and
maintenance immunosuppression with combination chemotherapy.

Alternate approaches that are still limited to animal models involve modulation of
specific proteins expressed on the cell surface of myeloid or lymphoid cells. For
example, overexpression of CD200 in combination with low-dose rapamycin
seems to improve skin and cardiac mouse allograft models [116]. In the skin,
certain types of DCs, such as epidermal Langerhans cells (LCs) and
plasmacytoid dendritic cells (pDCs) can induce tolerance [61, 117-119]. DCs are
also known to migrate between grafts and the host peripheral lymphoid organs
where they can initiate immune rejection or donor-specific tolerance. Thus,
donor-derived regulatory dendritic cell infusion in combination with CTLA4Ig
administration is also being studied and has been shown to prolong renal
allograft survival in rhesus macaques [120]. Another possible mechanism being
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investigated is the infusion of donor splenocytes and anti-CD154 antibody which
prolonged MHC-mismatched skin allografts in mice [105]. Modeled after these
pioneering studies, our investigation tests the ability of CD13 to modulate graft
rejection. CD13 is commonly up-regulated in sites of inflammation and has been
associated with certain inflammatory diseases [71]. Furthermore, our lab has
demonstrated that the inflammatory responses of CD13 null animals were
compromised upon challenge in various injury models [77, 78, 83, 90]. Given
these observations, a systematic study of CD13 in the context of the skin allograft
model may reveal a potential influence on transplant immune reactions.

3.2 Results
Hypothesis
Absence of CD13 will enable prolonged skin graft survival.

Absence of CD13 supports perpetual miHC mismatched skin graft survival
The murine skin graft model stringently tests potential immune modulators and is
a relatively uncomplicated surgical procedure located superficially, making it the
ideal model to determine the ability of CD13 to affect the acceptance of
transplant outcome [98]. Using wild type and global CD13 null mice in a standard
model of minor histocompatibility (MiHC) mismatched allograft rejection (Figure
2.2 and Table 2.2), we consistently observed improved survival of full-thickness
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CD13 null male donor skin grafts on female recipients (Figure 3.1A). In long term
studies, CD13 null grafts survived in both WT and CD13 null hosts in gendermismatched models for over 100 days (Figure 3.1B). Specifically, the CD13 null
grafts maintained their original size of ~8mm as compared to WT skin grafts,
which withered and gradually diminished in diameter until fully rejected between
two to three weeks post-transplant (Figure 3.2). Furthermore the CD13 null grafts
retained the characteristic thin, vascularized skin of the donor dorsal ear skin and
did not adopt the characteristics of host dorsal skin, such as increased skin
thickness and more robust fur. Interestingly, absence of CD13 was not sufficient
to maintain major histocompatibility mismatched allografts long-term; however
the absence of CD13 did prolong survival over WT counterparts (Figure 3.3).

CD13 null grafts demonstrate less inflammation
These observations suggested that CD13 may be a potential instigator of
allograft rejection. Indeed, while there was evidence of low-grade inflammatory
changes in CD13 null graft tissue after one week, the number of infiltrating cells
and the extent of tissue damage was significantly less than that observed in WT
skin grafts (Figure 3.4). Moreover, the dermis of the CD13 null grafts on CD13
null hosts was still primarily composed of dense irregular collagen filaments and
contained hair follicles as well as secretory glands. Immunohistochemical
quantification of CD3 positive cells in grafts at five days post-transplant indicated
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that significantly more T cells infiltrated into WT grafts as compared to CD13 null
grafts in both WT and CD13 null recipients (Figure 3.5).

Flow cytometry analysis of skin grafts and draining lymph nodes at day 5 posttransplant supported histological findings (Figure 3.6). CD13 null grafts contained
lower numbers of CD8+ T effector cells while their draining lymph nodes
contained higher numbers as compared with WT graft tissue and recipient
draining lymph nodes. Furthermore, CD13 null grafts contained higher numbers
of reparative M2 macrophages and lower numbers of inflammatory M1
macrophages (Figure 3.6). Notably, flow cytometric analyses of host spleens
receiving grafts of either genotype at day 5 post-transplant indicated that there
were no significant differences in splenic T cell or myeloid populations (Figure
3.7).

Transient blockade of CD13 prolongs graft survival
To confirm that the effects on transplant acceptance were attributable to CD13,
we used a CD13 blocking antibody, SL13, in transient treatment studies (Figure
2.3). Following two weeks of intraperitoneal monoclonal antibody administration,
SL13 was detected in the serum of treated mice, but not in the serum of mice
treated with vehicle alone (Figure 3.8). All of the mice tolerated the treatment and
after two weeks there were no significant pathological changes in any major
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organs indicating that SL13 can be used safely in vivo (data not shown). After the
two week treatment period, SL13 treatment was withdrawn and WT female
recipients of both groups received gender-mismatched skin grafts from WT and
CD13 null male donors. WT male recipients served as positive controls.

Similar to our findings in the global CD13 null animals, CD13 null grafts
universally survived until time of harvest in both groups (Figure 3.9). Also,
syngeneic grafts between male donor skin and male recipients performed equally
well. Importantly, rejection of WT male skin was delayed by 3 weeks in SL13treated WT female recipients; well after WT skin grafts had been rejected by the
untreated mice (Figure 3.9). This reversal of graft acceptance following the
withdrawal of SL13 treatment causally linked CD13 blockade to improved
allograft survival.

3.3 Discussion
CD13 is reported to be associated with a variety of inflammatory conditions.
Increased CD13 presence and activity has been described for patients with
various collagen vascular diseases including rheumatoid arthritis, systemic
sclerosis and systemic lupus erythematosus [121]. Higher percentages of
patients who have been infected with cytomegalovirus and also have Crohn’s
disease or ulcerative colitis have anti-CD13 autoantibodies [89]. Certain
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polymorphisms of CD13 has been linked to increased arterial hypertension in
humans [122]. CD13 expression and enzymatic activity has been found on highly
metastatic melanoma cells, colon cancer cells, breast cancer cells, and ovarian
cancer cells [123-126]. Despite all of these affiliations with inflammatory
diseases, CD13 has yet to be studied in the context of transplant rejection.

We believe that CD13’s active role in inflammation makes it a prime candidate to
target for immune modulation. Thus, we hypothesized that the absence or
obstruction of CD13 function will prolong graft survival in skin allotransplant
animal models. Indeed, CD13 null grafts not only survived indefinitely in miHC
mismatched transplants (Figure 3.1 and 3.2), but also demonstrated less
inflammatory changes (Figure 3.4). Prolonged miHC mismatched transplant
survival could also be achieved transiently with the administration of a CD13
blocking antibody (Figure 3.9). These data directly link the absence of CD13 to
extended graft survival. Indeed, the diminished cytotoxic T cell infiltration into
CD13 null grafts implied that the absence of CD13 abrogated the final effector
mechanism of rejection, which is the cytolytic T cell-mediated destruction of
foreign cells (Figure 3.5 and 3.6). The exact part along the immune cascade
leading to this final effect must be determined with additional studies looking at
donor and recipient immune cell trafficking between the graft and peripheral
lymphoid organs.
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Interestingly, the macrophage population within CD13 null grafts seems to
support the hypothesis and the absence of CD13 diminishes inflammation.
Macrophages originate from circulating peripheral blood monocytes, which
migrate to specific tissues and mature into either M1 classically activated or M2
alternatively activated phenotypes depending on local stimuli [127]. M1
macrophages are typically considered to promote inflammation by producing high
levels of inflammatory cytokines IL-1β, TNFα and expressing high levels of
inducible Nitric Oxide Synthase (iNOS) [128]. On the other hand, M2
macrophages produce more anti-inflammatory cytokines, such as TGFβ and IL10, and have been found to predominate in later reparative stages of wound
healing [129]. Flow cytometry analysis of macrophage populations in MiHC
mismatched grafts indicate higher levels of M2 and lower levels of M1
macrophages in CD13 null grafts (Figure 3.6). This provides more evidence that
the absence of CD13 promotes a less inflammatory microenvironment, which
would be more conducive to healing and less likely to reinforce rejection.

Surprisingly, splenic T cell and myeloid cell populations in recipients of CD13 null
and WT grafts seemed to be largely undisturbed at day 5 post-transplant (Figure
3.7). As the largest peripheral lymphoid organ in the body, the spleen is one of
the most important sources of mature primed T and B cells that enter circulation,
thus, playing a dual role in providing tolerance-inducing cells as well as graft
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rejecting effector cells [130]. As such, we had anticipated seeing differences in
the cytotoxic T cell population and possibly the myeloid compartment in
recipients of CD13 null versus WT grafts. Lack of quantifiable changes in the
spleen, however, may be attributed to the possible absence of splenic
involvement in CD13 mediated immunomodulation. Alternatively, the spleen may
harbor small differences in T cell or myeloid subsets at a later time point and will
require analysis with a larger panel of markers to discriminate between various
subpopulations.

While lack of CD13 was not enough to prevent rejection in MHC mismatched
models (Figure 3.3), CD13 null grafts were able to survive longer than WT skin
grafts, indicating that some level of immunomodulation was still occurring, but
was not enough to overcome the MHC-induced immune reactions. Cumulatively,
the miHC and MHC mismatch skin graft data demonstrate that CD13 is involved
in immunogenicity of allografts.

The importance of CD13 on graft-resident

immune cells versus other donor cells is still unknown, but studies on the
induction of tolerance through transient overexpression of CD200 or infusion of
soluble CD200 allude to a possible mechanism [116]. These reports show that
engagement of CD200 receptors which are expressed on the surface of dendritic
cells, mast cells and T regulatory cells led to a decrease in cytotoxic T cellmediated skin graft rejection, but was not required after graft acceptance had
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been established [131]. Similarly, CD13 is highly expressed on myeloid cells and
mast cells, suggesting that the inverse scenario may explain SL13-mediated
prolonged allograft survival. Thus, the SL13 treatment data testifies that targeting
CD13 is a viable option for the development of immune-modulating therapies in
not only organ transplantation, but also for the various cell therapies currently
being developed in the field of regenerative medicine.
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3.4 Figures and Legends
FIGURE 3.1 – GROSS IMAGES OF WT AND CD13 NULL SKIN GRAFTS IN WT
RECIPIENT MICE
FIGURE 3.2 – SKIN GRAFT SURVIVAL IN MIHC MISMATCH MODELS
FIGURE 3.3 – ALLOGRAFT SURVIVAL IN MHC MISMATCH SKIN GRAFTS
FIGURE 3.4 – HISTOLOGY OF SKIN GRAFTS
FIGURE 3.5 – QUANTIFICATION OF IMMUNOHISTOCHEMISTRY FOR T CELL
INFILTRATION IN SKIN GRAFTS
FIGURE

3.6

–

FLOW

CYTOMETRIC

ANALYSIS

OF

SPLEENS

IN

TRANSPLANT RECIPIENTS
FIGURE 3.7 – FLOW CYTOMETRIC ANALYSIS OF SKIN GRAFTS AND
DRAINING LYMPH NODES
FIGURE 3.8 – VERIFICATION OF SL13 PERSISTENCE IN SERUM OF
TREATED MICE BY IMMUNOCYTOCHEMISTRY
FIGURE 3.9 – MACROSCOPIC IMAGES OF MIHC MISMATCH SKIN GRAFTS
IN SL13 TREATED RECIPIENTS
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Figure 3.1 Gross images of WT and CD13 null skin grafts in WT recipient
mice. Two separate cohorts of 4 different miHC mismatched groups with four
mice per group were tracked for skin graft survival past 100 days. Survival was
determined by maintenance of original graft size (all originally 8mm) and
characteristic lack of thick fur as well as connection to host vasculature.
Representative images at days (A) 25 post-transplant and (B) 100 posttransplant. WTWT = WT graft, WT host; KOWT = CD13 null graft, WT host.
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Figure 3.2 Skin graft survival in minor histocompatibility mismatch models.
Skin graft diameters were measured in n=3 mice for 4 separate experimental
groups at 6 different time points. WTWT= WT graft, WT recipient; KOWT= KO
graft, WT recipient; WTKO= WT graft, KO recipient; KOKO= KO graft, KO
recipient. Error bars represent standard error of the mean.
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Figure 3.3 Allograft survival in major histocompatibility mismatched skin
grafts. 1 cohort of 4 experimental groups of n=4 mice per group were monitored
for graft survival over time after receiving strain mismatch transplants. Number of
mice with viable grafts were recorded at four different time points. WTWT= WT
graft, WT recipient; KOWT= KO graft, WT recipient; WTKO= WT graft, KO
recipient; KOKO= KO graft, KO recipient.
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Figure 3.4 Histology of skin grafts. Hematoxylin-Eosin staining of formalinfixed paraffin embedded skin graft tissues show overall graft tissue architecture.
These are representative images at day 5 after transplant. WTWT= WT graft, WT
host; KOWT= KO graft, WT host; WTKO= WT graft, KO host; KOKO= KO graft,
KO host. Scale bar = 100μm.
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Figure 3.5 Quantification of immunohistochemistry for T cell infiltration in
skin grafts. T cell infiltration was evaluated by immunohistochemistry and
quantification of CD3 positivity. Graft sections from miHC mismatch assays were
stained with an anti-CD3 antibody (representative images on top) and quantified
with Image Pro Plus and Prism Graphpad software (bottom). WTWT= WT graft,
WT host; KOWT= KO graft, WT host; WTKO= WT graft, KO host; KOKO= KO
graft, KO host. Scale bar = 100μm. n=3, p<0.0001
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Figure 3.6 Flow cytometric analysis of skin grafts and draining lymph
nodes. T cell and myeloid presence in graft tissue and draining lymph nodes at
day 5 post-transplant were assessed by flow cytometry quantification of cells
immunostained according to the panel in Table 2.3. Due to technical difficulties
n=3 mice per group were pooled. WTWT= WT graft, WT host; KOWT= KO graft,
WT host; WTKO= WT graft, KO host; KOKO= KO graft, KO host.
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Figure 3.7 Flow cytometric analysis of spleens in transplant recipients.
T cell and myeloid presence in recipient spleens at day 5 post-transplant were
assessed by flow cytometry quantification of cells immunostained according to
the panel in Table 2.3. 4 cohorts of n= at least 2 mice per experimental group
were analyzed with Graphpad Prism software. Cytotoxic T cells WTWT = 0.9950
± 0.1493, KOWT = 0.9275 ± 0.1008, WTKO = 0.9300 ± 0.01528, KOKO = 0.9633
± 0.05487; p = 0.9617. Monocyte WTWT = 1.206 ± 0.3789, KOWT = 1.306 ±
0.1141, WTKO = 1.007 ± 0.06859, KOKO = 0.9733 ± 0.08772; p = 0.5785.
Dendritic cells WTWT = 0.5642 ± 0.1986, KOWT = 0.7652 ± 0.1532, WTKO =
1.246 ± 0.1549, KOKO = 1.119 ± 0.2042; p = 0.0560
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Figure 3.8 Verification of SL13 persistence in serum of treated mice by
immunocytochemistry. Immunocytochemistry using serum from vehicle or
SL13 treated mice as the source of primary antibody and C33a human cells
engineered to express mouse CD13 as the cells. Sera were collected after 2
weeks of regular treatment. Monoclonal SL13 at a dilution of 1:1000 was used as
a positive control. Scale bar = 100μm.
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Figure 3.9 Macroscopic images of MiHC mismatch skin grafts in SL13
treated recipients. 1 cohort of 4 experimental groups of n=3 mice per group
were monitored for graft survival over time after receiving miHC mismatch skin
grafts following SL13 or vehicle treatment. Male hosts in addition to CD13 null
grafts were used as positive controls.
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Chapter 4

CD13 and Mouse Embryonic Stem Cells
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4.1 Introduction
The development of readily usable stem cell derived therapies is the impetus
driving regenerative medicine. Decades of donor organ shortages and
suboptimal post-operative long-term benefit have resulted in a critical, unmet
medical need that spans the whole realm of transplantation: an abundant source
of readily applicable, non-immunogenic donor tissue. With their infinite ability to
proliferate and differentiate into all types of cells, pluripotent stem cells (PSCs)
have been viewed by scientists as the answer to this problem. Following the
profundity of research published on stem cell derived treatments in animal
models, the lay public has also embraced PSCs as a potential cure for many
degenerative diseases and traumatic injuries.

Yet, using stem cells to cure a person of disease is not a new concept and has
existed in the form of bone marrow transplant therapy for hematopoietic
malignancies since the 1970s [132]. Over the years, through collaborative efforts
between immunologists and clinicians, the process of hematopoietic stem cell
(HSC) transplantation has been refined to address issues such as ease and
efficiency of donor cell collection by the implementation of cytokine stimulation
and peripheral blood drawing, acute rejection by extensively characterizing HLA
haplotypes, and development of graft versus host disease by invention of postharvest techniques including T cell depletion [133, 134]. This evolution is ongoing
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and there are still many challenges that need to be overcome before the
realization of a complication-free, long-term cure.

In many respects, the continuous modification of this one therapeutic modality is
a microcosm exemplifying similar transformations in the rest field of stem cell
therapeutics and the interdisciplinary collaborations that have emerged between
this and other specialties. Broadly speaking, exogenous stem cell therapies
consist of pluripotent and non-pluripotent cell-derived products. Previous
decades of experience with HSC transplantation has facilitated novel applications
of bone marrow derived cells in clinical settings such as treatment of acute and
chronic myocardial infarction [25, 135]. In addition to optimizing the therapeutic
benefit of these adult stem cells described in earlier chapters, experts in the field
are actively pursuing the transition of pluripotent stem cells from preclinical in
vitro and animal models to human clinical trials.

Since the first derivation of mouse embryonic stem cells (ESCs) in 1981 and
human ESCs in 1998, ESCs have consistently demonstrated an unlimited
potential to proliferate, maintain genomic stability over many passages in culture,
and differentiate into every cell lineage of the body [136, 137]. Indeed, several
protocols are now well established, some are even commercially available as
kits, for the generation of cells as diverse as dopaminergic neurons, beating
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cardiomyocytes, hematopoietic cells, pancreatic beta cells, and vascular
endothelial cells [138-141]. Unfortunately, being allogeneic, their utility in the
clinic is hampered by the same immunologic reactions that limit current
transplantation therapies, except for certain immune privileged sites such as the
eye for retinal pigment epithelial cells [38, 142].

The second pluripotent stem cell source, termed induced pluripotent stem cells
(iPSCs), were more recently developed in 2006 and 2007 using mouse and
human fibroblasts [143, 144]. Originally established by painstaking work
identifying four critical pluripotency-inducing transcription factors, Oct4, Sox2,
Klf4 and cMyc, this protocol has been replicated independently in labs all over
the world and is now sold as bullet kits for the conversion of any mature cell type
into pluripotent stem cells. Unlike ESCs, iPSCs can be generated by a variety of
methods that may involve viral integration of DNA, expression of non-integrating
episomal DNA, integration and subsequent excision of DNA as well as numerous
RNA-based techniques and even a protein based protocol [145-150]. Once the
lines are established, iPSCs are reported to behave similarly to their ESC
counterparts and can also be differentiated into specific lineages, such as
cardiomyocytes, according to the many published protocols and commercially
available kits [151, 152].
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These two pluripotent sources of cells each have their strengths and weaknesses
when considering them for clinical application. iPSCs are autologous, which
obviates the need for immune suppression of patients receiving the therapy;
however, there is considerable time between harvesting cells from and delivering
the final product to the patient because of the time required to reprogram the
cells to pluripotency and then differentiate them into the mature cell type.
Furthermore, iPSCs generated from patients suffering from genetic diseases
recapitulate disease specific phenotypes and thus will require gene correction
before therapeutic application [153-156].

Alternatively, ESCs are already established cell lines that have been extensively
characterized for genetic abnormalities and can be used immediately, especially
if they are already the differentiated cell type that is required for the particular
situation. Unfortunately, having been established from embryos, ESCs are
allogeneic and require the issue of immunogenicity to be addressed. In response,
the fields of gene therapy and cell therapy have united to create genetically
modified ESCs that are not immunogenic, but this entails virus-mediated genetic
modification

of

immune-regulating

genes,

which

necessitates

stringent

verification of safety [157-159]. Indeed, the transplant of hESCs genetically
engineered to overexpress cytotoxic T-lymphocyte antigen 4 immunoglobulin
(CTLA4-Ig) as well as programmed death ligand-1 (PD-L1) into humanized
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mouse models led to the formation of highly differentiated teratomas with
significantly lower T cell infiltration [157]. Interestingly, the modulation of only one
of these factors was not enough to prevent immune rejection, implying that
targeting several specific but distinct pathways may be necessary to produce
optimal results. Based on our findings that the absence of CD13 in skin
transplants leads to prolonged graft survival and diminished inflammation,
manipulation of CD13 expression in ESCs and ES-derived cells may contribute to
the generation of a universal donor pluripotent stem cell source from which a
ubiquitously applicable off-the-shelf product can be developed.

4.2 Results
Hypothesis
Differentiated cells derived from mESC lacking CD13 are not rejected by
immune-competent mice.

CD13 null mESCs display typical characteristics of pluripotent stem cells.
To determine if CD13 blockade could be applied in a stem cell-derived
therapeutic setting, we generated mouse ESCs from WT and CD13 null mice.
These cells displayed characteristic mES cell morphology, traditionally described
as a large nucleus to cytoplasm ratio, and expressed traditional pluripotency
markers OCT4 and NANOG (Figure 4.1). Both WT and CD13 null mESCs
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proliferated at similar rates in vitro and were able to form uniformly sized
embryoid bodies by the hanging drop method (Figure 4.2). Furthermore, all ES
lines produced cell types from the three embryonic germ layers when
differentiated in teratoma assays (Figures 4.3).

CD13 null mESCs are not rejected in immune competent mice
Teratoma formation in immune-compromised mice, such as athymic nude or nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, has
historically been used to demonstrate pluripotency of stem cell lines; however,
recently, this assay has been harnessed to determine immunogenicity of certain
PSC lines using immune competent mice [160, 161]. Accordingly, WT and CD13
null mESCs were subcutaneously injected into allogeneic, immune-competent
hosts. After 4-6 weeks, CD13 null mES consistently expanded into substantially
larger teratomas than WT mES (Figure 4.4). Indeed, CD13 null teratomas were
almost three times larger, despite equal starting cell numbers and growth
duration as well as bilateral injection into the same host mice in four separate
cohorts consisting of at least three mice per genotype. Unlike their equal in vitro
proliferation rate compared to WT mES, the CD13 null mES-derived cells in the
teratomas proliferated at higher levels as indicated by increased Ki67 staining
and BrDU incorporation (Figures 4.5 and 4.6), but did not display any significant
apoptosis by Apoptag staining (Figure 4.7). Furthermore, CD13 null teratomas
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were also more vascularized as detected by endothelial CD31 expression and
pericyte αSMA staining (Figure 4.8).

Overall, similar to our observations with CD13 null skin grafts, these data suggest
that CD13 null mES possess a survival advantage over WT mES. To ascertain
the potential immunological processes underlying this apparent growth
advantage, WT and CD13 null mES were injected subcutaneously into
immunocompromised mice lacking T, B and NK cells. Without host immune
interference, both WT and CD13 null mES generated teratomas of equal size and
complexity at similar rates (Figure 4.9) confirming that the difference in growth
was not attributable to inherent differences in the embryonic stem cells
themselves, but rather to events occurring at the donor-host interface.

Analysis of infiltrating CD3+ T cells in teratomas formed in immune competent
mice was higher in WT than in CD13 null teratomas (Figure 4.10). Extending this
comparison to host genotype revealed highly significant differences in numbers
of infiltrating T cells in teratomas generated in CD13 null hosts. Additionally,
higher levels of dendritic cells and macrophages were detected in WT teratomas
(Figure 4.11). Cumulatively, this data implies that WT mES are more capable of
stimulating an immune reaction against the transplanted cells and that the
response of CD13 null mice to immunogenic donor cells is impaired which is also
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in agreement with our immune cell analyses in our skin graft studies.

4.3 Discussion
A significant obstacle in the transition of embryonic stem cell derived therapies
from animal models into human trials is the anticipated immune-mediated
rejection of allogeneic tissue. Proposed solutions generally harness the power of
inducing tolerance by establishing donor-specific hematopoietic microchimerism
or creating non-immunogenic transplants from stem cells that express key
immune-modulating factors [112, 157]. Based off of observations from our skin
graft studies, we hypothesized that mESCs lacking CD13 expression may also
thrive in immune-competent hosts. Indeed, teratomas generated from CD13 null
mESCs grew to be much larger (Figure 4.4) and demonstrated higher rates of
proliferation (Figures 4.5 and 4.6) than WT mESCs despite comparable in vitro
characteristics (Figures 4.1 and 4.2).

This

difference

in

growth

could

be

directly

attributed

to

diminished

immunogenicity of CD13 null mESCs as injection into nude mice abolished the
growth advantage (Figure 4.9). Immune involvement was further supported by
the increased infiltration of T cells and myeloid cells into WT teratomas (Figures
4.10 and 4.11). The immunogenicity of pluripotent stem cells has also been
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demonstrated by others using allogeneic teratoma formation assays [161, 162].
These studies also demonstrate increased T cell mediated rejection, but the
exact mechanism cannot be determined from these data. Given the complexity of
teratoma cell composition, dissecting the exact mechanism by which CD13
modulates immune responses to transplants is better executed in the more
established and less complicated skin graft model or through in vitro assays.

Taken as a whole, our data indicates that the absence of CD13 in transplanted
cells, regardless of cell type, seems to confer immunologic advantage. Future
studies involving the differentiation of CD13 null mESCs into organ-specific cell
types followed by orthotopic administration of those cells are necessary to
confirm applicability of this observation to actual cell therapy. Furthermore,
generation of human pluripotent stem cells lacking CD13 is paramount not only to
validate that CD13 modulation is a viable mechanism in humans, but also to
facilitate the transition of this modality into the clinic.
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4.4 Figures and Legends
FIGURE 4.1 – IMMUNOFLUORESCENT IMAGES OF PLURIPOTENCY
MARKER EXPRESSION IN MESCS
FIGURE 4.2 – QUANTIFICATION OF IN VITRO PROLIFERATION OF MESCS
AND REPRESENTATIVE IMAGES OF EBS
FIGURE 4.3 – TERATOMA HISTOLOGY
FIGURE 4.4 – MACROSCOPIC IMAGES OF TERATOMAS
FIGURE 4.5 – QUANTIFICATION OF IMMUNOHISTOCHEMISTRY FOR KI67
EXPRESSION IN TERATOMAS
FIGURE 4.6 – QUANTIFICATION OF IMMUNOFLUORESCENCE FOR BRDU
INCORPORATION IN TERATOMAS
FIGURE 4.7 – APOPTAG STAINING OF TERATOMAS
FIGURE 4.8 – QUANTIFICATION OF TERATOMA VASCULATURE
FIGURE 4.9 – MEASUREMENT AND REPRESENTATIVE HISTOLOGY OF
TERATOMA FORMATION IN IMMUNE-COMPROMISED MICE
FIGURE 4.10 – IMMUNOSTAINING AND QUANTIFICATION OF T CELL
INFILTRATION IN TERATOMAS
FIGURE 4.11 – FLOW CYTOMETRIC ANALYSIS OF MYELOID INFILTRATION
IN TERATOMAS
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Figure 4.1 Immunofluorescent images of pluripotency marker expression
in mESCs. OCT4 and NANOG expression were evaluated in WT and CD13 null
mESCs by immunofluorescence. Green staining indicates positivity for OCT4 or
NANOG. Blue staining indicates DAPI nuclear counterstain. All ES lines were
evaluated. Representative images are above. Scale bar = 50μm
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Figure 4.2 Quantification of in vitro proliferation of mESCs and
representative images of EBs. WT and CD13 null ESCs were evaluated for
embryoid body formation by hanging drop method in vitro. Representative
images at 48 hours indicate no significant growth difference between the two
lines. Scale bar = 100μm. MTT assays were performed in triplicate for WT and
CD13 null mESCs over the course of 12 days. Absorbances were analyzed with
Prism Graphpad software.
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Figure 4.3 Teratoma histology. Hematoxylin-Eosin staining was performed on
teratoma tissue sections to determine the presence of cell types derived from
endoderm, mesoderm, and ectoderm. Both WT (top row) and CD13 null (bottom
row) mES formed cell types indicative of all three embryonic germ layers.
Ectodermal stratified epithelium, mesodermal chondrocytes and endodermal
ciliated epithelium could be found in all tissue sections.
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Figure 4.4 Macroscopic images of teratomas. Teratoma formation was
assessed for WT and CD13 null mESCs. 4 separate cohorts with 4 experimental
groups of n = at least 3 mice were conducted. Representative images were taken
at time of harvest, which was four weeks after subcutaneous injection.
Scale bar = 1cm.
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Figure 4.5 Quantification of immunohistochemistry for Ki67 expression in
teratomas. In vivo proliferation of WT and CD13 null mESCs was assessed by
immunohistochemistry staining for Ki67 followed by quantification and analysis
using Image Pro Plus and Prism Graphpad. (n=5 animals from 2 experimental
replicates, error bars represent SEM, p=0.01) Scale bar = 100μm.
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Figure 4.6 Quantification of immunofluorescence for BrDU incorporation in
teratomas. In vivo proliferation of WT and CD13 null mESCs was assessed by
immunofluorescent staining for BrDU incorporation followed by quantification and
analysis using Image Pro Plus and Prism Graphpad. (n=5 animals from 2
experimental replicates, error bars represent SEM, p=0.0006).
Scale bar = 100μm.
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Figure 4.7 Apoptag staining of teratomas. Immunostaining for apoptosis was
imaged but not quantified due to the lack of positive staining. One cohort of 4
experimental groups of n=2 mice each was assessed. Scale bar = 100μm.
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Figure 4.8 Quantification of teratoma vasculature. In vivo vascularity of WT
and CD13 null mESCs was assessed by immunohistochemical staining for CD31
positive endothelium and surrounding aSMA positive smooth muscle cells
followed by quantification and analysis using Image Pro Plus and Prism
Graphpad. (n=5 animals from 2 experimental replicates, error bars represent
SEM). For CD31: p<0.0001 for all groups. For aSMA: p<0.0001 between mES
genotypes in WT mice, no significant difference between WT and CD13 null mES
in CD13 null hosts, p=0.03 between host genotypes.
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Figure 4.9 Measurement and representative histology of teratoma
formation in immune-compromised mice. CD13 null and WT mES teratoma
formation was evaluated in immune-compromised mice over the course of 3
weeks. Representative H&E images indicate the formation of tissues
representing all three embryonic germ layers. Tumor volume was analyzed using
Prism Graphpad and displayed no significant statistical difference. (n=5 mice in
one cohort)
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Figure 4.10 Immunostaining and quantification of T cell infiltration in
teratomas. T cell infiltration into WT and CD13 null teratomas was assessed by
immunohistochemical staining for CD3 positive cells followed by quantification
and analysis using Image Pro Plus and Prism Graphpad. (n=6 animals from 2
experimental replicates, error bars represent SEM, p=0.0085).
Scale bar = 100μm.
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Figure 4.11 Flow cytometric analysis of myeloid infiltration in teratomas.
WT and CD13 null teratomas were dissociated into single cells and stained
according to the antibody panel in Table 2.3 and analyzed with Flojo software.
Representative quantification from one cohort is shown above.
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Chapter 5

Mast Cells and Transplant Survival
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5.1 Introduction
Mast Cells
Since their first discovery over 130 years ago by Paul Ehrlich, mast cells (MCs)
have been extensively characterized in terms of their pro-inflammatory and
allergic reactions. Originating from a CD34+ckit+CD13+ myeloid progenitor in the
bone marrow [163], committed mast cell progenitors circulate throughout the
body before taking residence in virtually all tissues, especially those in contact
with the external environment such as the skin, lungs, and intestines, where they
mature and start expressing high levels of cKit, CD13 and FcεR [164, 165].
Mature mast cells have a half-life of at least 40 days, but can survive for months
and also proliferate locally in response to certain growth factors such as IL-3 and
SCF in rodents and IL-6 in humans [166]. Thus, while all mast cells originate from
the bone marrow, within a particular tissue, mature mast cells result from both
recruitment of circulating progenitors and proliferation of resident MCs.

Two main classification systems broadly separate mast cells into two subtypes
depending on their final location or primary granule contents. In mice, based on
their location in the intestinal submucosa, skin, peritoneal cavity and perivascular
interstitium, connective tissue mast cells (CTMCs) are distinguished from
mucosal mast cells (MMCs), which are mostly found between epithelial cells in
the lung and intestinal wall [167]. Alternatively, in humans, these two categories
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can be renamed according to granule contents consisting primarily of trypase
only in MCT (analogous to mouse MMCs) or chymase and tryptase in MCTC
(analogous to mouse CTMCs) [168]. Interestingly, these different subtypes also
produce different bioactive mediators of inflammation. CTMCs contain high levels
of heparin and histamine, which allow them to initiate potent vasoactive
responses to allergens, while MMCs contain no heparin and very low levels of
histamine. The list of MC-derived products and their activities seems to grow with
each new study that is published, but the broad categories of mediators include
granule-associated products (such as histamine, heparin, tryptase and
chymase), growth factors (such as vascular endothelial growth factor (VEGF) and
fibroblast growth factor (FGF)), cytokines (such as tumor necrosis factor α (TNF
α), interleukin-1 (IL-1), and interferon-γ (IFNγ)), chemokines (such as CCchemokine ligand 5 (CCL5) and CXC-chemokine ligand 10 (CXCL10)), lipid
mediators (such as leukotrienes LTC4 and LTB4), and nitric oxide and superoxide
radicals [166]. Each of these factors executes one or more MC activities, but the
specific action that gets initiated is context dependent.

Mast cells respond in several different ways to various types and amounts of
stimuli they receive. For instance, resting MCs can bind IgE antibodies to
become sensitized, which allows them to rapidly degranulate upon stimulation
with specific antigens. Alternatively, MCs also express toll-like receptors (TLRs),
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which allow MCs to recognize pathogen associated molecular patterns (PAMPs)
and damage associated molecular patterns (DAMPs) and release cytokines,
chemokines and lipid mediators without degranulation. Additionally, MCs also
respond to complement mediators C3a and C5a with rapid degranulation, but
diminished release of cytokines and lipid mediators [167]. Furthermore, MC
location and microenvironment seem to affect their mediator profile, in that
transfer of one type of mast cell to a different location leads to the adoption of the
characteristics of MCs in that tissue type and MCs constantly exposed to
inflammation alter their contents [166, 169]. Overall, MCs display a high level of
plasticity that allows them to perform the correct stimulus-specific functions at a
particular location.

Mast cell preference for tissues in contact with the external environment makes
them prime actors in the first response to pathogens and allergens. Within their
resident organs, mast cells also specifically migrate close to blood vessels, which
facilitates their function in recruiting neutrophils, dendritic cells and T cells as well
as

promoting

angiogenesis,

edema

or

bronchoconstriction.

Thus,

MC

involvement in antibacterial and antiparasitic responses, chronic inflammatory
disorders (such as rheumatoid arthritis and atherosclerosis), or allergic diseases
(such as asthma), is not surprising; however, an unexpected role for MC has
recently been identified in transplant immunity [170-174].
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Mast Cells in Transplantation
Mast cells are critical for allograft survival [175, 176]. While the exact mechanism
allowing MCs to exert such effects are still unclear, a direct relationship between
MCs and T regulatory cells seems to be the driving force inducing donor-specific
tolerance. Indeed, in the c-kit null mast cell deficient mouse model (Wsh),
tolerance to skin allografts could not be established through donor-specific
transfusion and anti-CD154 administration, a protocol that is highly effective in
WT mice, and adoptive transfer of mast cells into these mice was enough to
rescue this phenotype [176]. Furthermore, degranulation of MC either locally or
systemically reverses tolerance to previously established skin allografts by
transiently diminishing the ability of T regulatory cells to suppress T effector cell
activity [177]. Importantly, MC degranulation, and not simply the creation of an
inflammatory microenvironment, was the causal event leading to the rejection of
allografts [177]. Given these findings and the fact that mast cells express high
levels of CD13, a similar mast cell mediated mechanism may explain our
observations of prolonged allograft survival in the absence of CD13.

5.2 Results
Hypothesis
CD13 null mast cells fail to degranulate and stimulate immune rejection.
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CD13 null allografts contain more intact mast cells
To determine the contribution of mast cells to our model of allograft survival, we
examined WT and CD13 null skin grafts for the presence of mast cells and their
degranulation status using toluidine blue to stain mast cell-specific granular
contents. Similar to findings published by other groups studying different cell
surface modulators of immunity, there were higher levels of toluidine blue
staining in the absence of CD13, which was supported by similar results
determined by c-Kit immunostaining (Figure 5.1). This increase in granule
staining was also seen in the draining superficial inguinal lymph nodes of mice
that had received the CD13 null skin grafts at day 5 post-transplant (Figure 5.2).
This abundance of intracellular metachromatic granule staining likely reflects the
reduced mast cell degranulation in the absence of CD13 as quantified by
counting the extracellular release of toluidine blue positive granules (Figure 5.3).

Interestingly, toluidine blue staining of WT skin that had started to be rejected in
SL13 treated mice indicated a lower number of intact mast cells to that seen in
CD13 null grafts (Figure 5.4), suggesting without CD13 blockade mast cell
degranulation can proceed; however, MC quantification of these grafts prior to
rejection must be completed before definitively making this conclusion. Toluidine
staining of teratoma sections also indicates higher levels of MC staining between
tumor lobules and in the interstitium around CD13 null teratomas, consistent with
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reduced mast cell degranulation in this model as well (Figure 5.5).

Absence of CD13 on mast cells corresponds to diminished mast cell
activation and degranulation in vitro
To confirm our in vivo observations of mast cell behavior in the absence of CD13,
we derived primary mast cells from bone marrow of WT and CD13 null mice
according to previously published protocols [97]. After 4-8 weeks of differentiation
in media containing IL-3, cultures consisted of 80-90% ckit+FcεR1α+ mast cells,
which displayed a high degree of forward and side scatter, indicating that these
cells are large and complex (Figure 5.6).

To test the response of mast cells to MiHC determinants, we co-cultured isolated
WT or CD13 null mast cells with gender-mismatched dermal fibroblasts and
assessed changes by flow cytometry. Not surprisingly, when appropriately
stimulated, the forward and side scatter profiles of both WT and CD13 null mast
cells were decreased indicating loss of granularity and size, which was
presumably the result of degranulation; however, the changes in CD13 null mast
cell size and granularity were significantly less upon stimulation with either WT or
CD13 null dermal fibroblasts than WT mast cells (Figure 5.7). Furthermore,
CFSE labeling of mast cells indicated that there was less mast cell proliferation in
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response to CD13 null dermal fibroblasts (Figure 5.8). This is analogous to
results from mixed lymphocyte reactions between gender mismatched MCs and
splenocytes where the response of splenocytes was considerably weaker when
stimulated with CD13 null cells, but the absence of CD13 on responding cells did
not affect their ability to proliferate (Figure 5.9).

β-Hexosaminidase release is commonly used as a surrogate marker for mast cell
stimulation and degranulation in vitro [178]. According to the mast cell-dermal
fibroblast co-culture stimulation assay, mast cells did not proliferate in response
to CD13 null dermal fibroblasts and CD13 null mast cells also demonstrated less
proliferation even when stimulated with WT dermal fibroblasts. To determine if
this lack of proliferation also corresponded to differences in degranulation
between WT and CD13 null mast cells, β-hexosaminidase activities in the
supernatants of stimulated mast cells stimulated were measured. Interestingly,
CD13 null mast cells stimulated with a functional antibody targeting the FcεR did
not release any β-hexosaminidase (Figure 5.10), even though the difference in
release between WT and CD13 null mast cells was not statistically significant. βhexosaminidase release from co-cultures of WT and CD13 null mast cells with
CD13 null dermal fibroblasts was also significantly lower than when stimulated
with WT fibroblasts (Figure 5.11). Surprisingly, β-hexosaminidase release was
high in the co-culture of WT DFs with CD13 null MCs, indicating that CD13 null
mast cells are capable of degranulation.
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5.3 Discussion
The importance of mast cell presence and activity in promoting transplant
tolerance is evident in a number of studies [158, 176]. The association of
accepted allografts with increased mast cell presence is also seen in CD13 null
transplants (Figures 5.1 and 5.5). Furthermore, in line with evidence that mast
cell degranulation leads to the prompt rejection of previously tolerated skin grafts
[177], CD13 null tissues displayed less evidence of degranulation (Figure 5.3),
indicating that a mast cell mediated mechanism may explain the prolonged
survival of transplanted cells lacking CD13. Decreased mast cell presence is also
seen in WT skin grafts that were beginning to be rejected in SL13-treated mice
(Figure 5.4), implying that withdrawal of CD13 blockade enabled mast cell
degranulation in transplants. Thus, we hypothesized that loss of CD13 on mast
cells may render them less sensitive to signals that stimulate degranulation,
favoring instead the creation of a more tolerogenic microenvironment.

CD13 is normally highly expressed on mast cells and to discover any intrinsic
differences between CD13 null and WT mast cells, primary mast cell cultures
were analyzed for their abilities to be stimulated and their readiness to stimulate
inflammation [97]. CD13 null mast cells at baseline seemed grossly normal,
displaying characteristic metachromatic granules and expressing c-Kit and FcεR
(Figure 5.6). Contrary to our hypothesis, the absence of CD13 on dermal
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fibroblasts seemed to be more important than its absence on mast cells in terms
of stimulating mast cell proliferation and degranulation (Figures 5.7, 5.8, and
5.11). Indeed the difference in β-hexosaminidase release between WT and CD13
null mast cells was not statistically significant when stimulating the cells with an
antibody to the FcεR (Figure 5.10). Furthermore, when mast cells were used to
stimulate splenocytes, the absence of CD13 on the mast cells seemed to be the
predominant factor determining splenocyte activation (Figure 5.9). While some of
the stimulation and proliferation assays must be repeated to determine statistical
significance, as a whole, these data show that CD13 null mast cell degranulation
and pro-inflammatory responses may be slightly impaired, but the absence of
CD13 on the stimulating cells is more likely the explanation for our observations
in CD13 null skin grafts and teratomas leading us to revise our hypothesis
accordingly. We now believe that the absence of CD13 expression on donor cells
prevents the activation of mast cell degranulation as well as host inflammatory
immune responses from occurring.
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5.4 Figures and Legends
FIGURE 5.1 – MAST CELL QUANTIFICATION IN SKIN GRAFTS
FIGURE 5.2 – MAST CELL STAINING AND QUANTIFICATION OF DRAINING
LYMPH NODES
FIGURE 5.3 – QUANTIFICATION OF DEGRANULATION IN SKIN GRAFTS
FIGURE 5.4 – MAST CELL QUANTIFICATION IN SL13 TREATED MICE
RECEIVING SKIN GRAFTS
FIGURE 5.5 – MAST CELL QUANTIFICATION IN TERATOMAS
FIGURE 5.6 – CHARACTERIZATION OF BONE MARROW DERIVED PRIMARY
MAST CELL CULTURES
FIGURE 5.7 – SIZE AND GRANULARITY OF PRIMARY MAST CELL
DETERMINED BY FLOW CYTOMETRY
FIGURE 5.8 – MAST CELL PROLIFERATION AFTER DERMAL FIBROBLAST
STIMULATION MEASURED BY CFSE DILUTION
FIGURE

5.9

–

SPLENOCYTE

PROLIFERATION

AFTER MAST

CELL

STIMULATION MEASURED BY CFSE DILUTION
FIGURE 5.10 – MEASUREMENT OF MAST CELL DEGRANULATION UPON
STIMULATION WITH ANTIBODY TO FCER
FIGURE 5.11 – MEASUREMENT OF MAST CELL DEGRANULATION AFTER
STIMULATION WITH DERMAL FIBROBLASTS
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Figure 5.1 Mast cell quantification in skin grafts. Toluidine blue staining and
immunohistochemistry for cKit expression was performed on miHC mismatched
skin graft tissue sections. Representative images of toluidine blue staining of WT
and CD13 null skin display mast cell presence in the skin at baseline. Scale bar =
100μm. Image Pro Plus software was used to determine relative staining.
Quantification of 2 separate cohorts of 4 experimental groups with 5 mice per
group was analyzed with Prism software. p<0.0001.
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Figure 5.2 Mast cell staining and quantification of draining lymph nodes.
Toluidine blue staining was performed on tissue sections of draining lymph nodes
of mice that had received miHC mismatched skin grafts. Representative images
of toluidine blue staining display mast cell presence in the lymph nodes. Scale
bar = 250μm. Toluidine positive mast cells were manually counted. Quantification
of 2 separate cohorts of 2 experimental groups with 3 mice per group was
analyzed with Prism software. p<0.0001.
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Figure 5.3 Quantification of degranulation in skin grafts. Toluidine blue
staining was performed on miHC mismatched skin graft tissue sections.
Representative images of extracellular toluidine blue positive granules in WT
grafts indicate degranulation of mast cells. Numbers of degranulating mast cells
were manually counted and normalized to the total numbers of mast cells present
in the field. Quantification of 2 separate cohorts of 4 experimental groups with 2
mice per group was analyzed with Prism software. p<0.0001. Scale bar = 10μm.

103

Relative Units

Toluidine)Blue)Quan-ﬁca-on
3
***
2

WT)gra3
KO)gra3

1

W
TW
T
PB
K
S
O
W
T
PB
W
S
TW
T
SL
K
13
O
W
T
SL
13

0

Donor-Host, Treatment
Figure 5.4 Mast cell quantification in SL13 treated mice receiving skin
grafts. Toluidine blue staining was performed on tissue sections from miHC
mismatched skin graft in SL13 or vehicle control treated mice. Image Pro Plus
software was used to determine relative staining. Quantification of 1 cohort
consisting of 4 experimental groups with n=3 mice per group was analyzed with
Prism software. p=0.0008.
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Figure 5.5 Mast cell quantification in teratomas. Toluidine blue staining was
performed on tissue sections of WT and CD13 null teratomas generated in WT
mice. Representative images display mast cell presence in the interstitial tissue
immediately surrounding tumors. Toluidine positive mast cells were manually
counted per field of view for one cohort of 2 experimental groups with 3 mice per
group was analyzed with Prism software (p=0.01). Scale bar = 20μm.
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Figure 5.6 Characterization of bone marrow derived primary mast cell
cultures. WT and CD13 null primary bone marrow derived mast cells were
cultured for 6 weeks in media containing IL-3. Representative images (left) show
development of toluidine blue positive metachromatic granules in MCs. Flow
cytometry for typical mast cell markers indicate the development of cKit and
FcεR1 double positive cells. TRAMP cells, which do not express cKit or FcεR1,
were also stained with the antibodies to serve as a negative control.
Scale bar = 20μm.
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Figure 5.7 Size and granularity of primary mast cells determined by flow
cytometry. WT and CD13 null BMDMC forward and side scatter profiles were
analyzed by flow cytometry before and after stimulation with WT dermal
fibroblasts. A high degree of FSC and SSC indicate the large size and
complexity, respectively, of naïve mast cells. Upon stimulation, MC size and
granularity decrease.
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Figure 5.8 Mast cell proliferation after dermal fibroblast stimulation
measured by CFSE dilution. WT and CD13 null BMDMC proliferation was
analyzed by flow cytometry for CFSE dilution after stimulation with WT and CD13
null dermal fibroblasts. Peaks with lower CFSE intensity indicate cells that have
divided.
Key: MC genotype-DF genotype
WTKO= WT MC, KO DF
KOWT= KO MC, WT DF
108

Percent%Dividing

Mast%Cell)Splenocyte%Prolifera4on
100
80
60
40
20

KO
KO

TK
O
W

KO
W
T

W

TW

T

0

Figure 5.9 Splenocyte proliferation after mast cell stimulation measured by
CFSE dilution. Quantification of splenocyte proliferation upon stimulation with
mast cells was measured by flow cytometry for CFSE dilution and analyzed with
Prism Graphpad software. Percent dividing cells reflects the percentage of the
live, CFSE positive population with lower CFSE intensity. Co-culture was
conducted in triplicate, but flow cytometry was performed on pooled samples.
Key: MC genotype-DF or splenocyte genotype
WTKO= WT MC, KO DF or splenocyte
KOWT= KO MC, WT DF or splenocyte
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Figure 5.10 Measurement of mast cell degranulation upon stimulation with
antibody to FcER. WT and CD13 null BMDMCs were stimulated with an FcεR1
functional antibody. Replicates of 9 were analyzed for β-hexosaminidase release
which is a common surrogate for evaluating mast cell degranulation. Percent
release was calculated for each replicate according to the formula indicated in
the methods and analyzed using Prism Graphpad software. No statistical
significance was found.
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Figure 5.11 Measurement of mast cell degranulation after stimulation with
dermal fibroblasts. WT and CD13 null BMDMCs were stimulated with WT or
CD13 null dermal fibroblasts. Replicates of 9 were analyzed for βhexosaminidase release and percent release was calculated for each replicate.
Analysis was completed using Prism Graphpad software (p<0.0001).
Key: MC genotype-DF genotype
WTKO= WT MC, KO DF
KOWT= KO MC, WT DF
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Chapter 6

Concluding Remarks
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6.1 Summary of Findings
The impact of CD13 on the survival of minor and major histocompatibility
mismatched allografts was determined using the well-established murine skin
graft model [98]. In agreement with our hypothesis, CD13 null skin grafts
functioned in both WT and CD13 null recipient mice long after WT skin grafts had
been fully rejected in minor histocompatibility mismatch models. Furthermore,
similar results were achieved by administration of a CD13-blocking monoclonal
antibody, SL13, but were lost upon withdrawal of treatment. Cellular analysis by
histology and flow cytometry of graft tissues at 5 and 7 days post-transplant
supported this observation as CD13 null grafts demonstrated less inflammatory
cytotoxic T cell and M1 macrophage infiltration with concomitant preservation of
normal skin architecture. Interestingly, reciprocal changes in cytotoxic T cell
numbers were found in the draining lymph nodes. No notable differences in were
observed in the spleens of tolerant recipients at day 5. While indefinite graft
survival

could

not

be

achieved

through

CD13

modulation

in

major

histocompatibility mismatched models, CD13 null tissues still persisted longer
than their WT counterparts, suggesting that some degree of immune modulation
is occurring due to the absence of CD13 activity.

The influence of CD13 on allograft survival could be extended to pluripotent stem
cell-derived tissues. Indeed, CD13 null mESCs repeatedly generated larger
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teratomas in both WT and CD13 null immune-competent hosts, but demonstrated
no growth advantage in immune-compromised nude mice. CD13 null teratomas
had higher levels of proliferation and vascularity upon quantification of Ki67,
BrDU, CD31 and αSMA expression in histological sections. Furthermore, CD13
null teratomas, like their skin graft counterparts, contained fewer infiltrating
inflammatory cells. None of these differences could be attributed to intrinsic
defects in CD13 null mESCs as in vitro proliferation was comparable to WT mES
proliferation rates and teratomas of both genotypes contained tissues of all three
embryonic germ layers. As a whole, these results indicate that targeting CD13
expression on stem cells will facilitate engraftment of stem cell-derived tissues by
diminishing initial inflammatory rejection.

Analysis of skin grafts and teratomas revealed an increase in mast cell presence
in CD13 null allografts by toluidine blue detection as well as c-kit immunostaining.
Upon closer analysis of toluidine-stained tissues, increased degranulation was
noted in WT grafts. Such observations involving mast cells have previously been
reported in other studies of allo-transplantation [177]. Evidence of mast cell
involvement in mediating our observations was further investigated in in vitro
studies using WT and CD13 null bone marrow derived mast cells. Upon coculture with WT and CD13 null dermal fibroblasts, BMDMCs demonstrated less
stimulation and degranulation when stimulated with CD13 null DFs. Furthermore,
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CD13 null BMDMC-stimulated splenocytes also proliferated to a lesser degree
than those stimulated with WT mast cells. While the exact mechanism by which
the absence of CD13 on stimulating cells modulates immune responses is still
unknown, these results cumulatively provide compelling reason to investigate
CD13-specific mechanisms that improve transplant survival.

6.2 Implications and Future Directions
To date, this is the first study identifying CD13 as a potential candidate for
targeted immunotherapies that promote allograft survival without the use of
traditional immunosuppressive pharmacologics. The data presented here clearly
demonstrate reduced numbers of cytotoxic T cell and inflammatory macrophage
presence in CD13 null grafts; however, the exact mechanism leading to these
events is yet to be determined. We have shown that absence of CD13 in donor
cells seems to diminish their ability to instigate inflammation. Future studies using
SL13 to block CD13 in donor cells, followed by mixed lymphocyte reactions and
measurements of inflammatory cytokine release in vitro may help dissect out the
pathways that are involved.

We have also identified CD13 null mast cells as an additional possible mediator
of this effect. Given that mast cells are known to produce IL-4, a known stimulator
of reparative M2 macrophages [127], and IL-10, a potent immunosuppressor, it is
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possible that the diminished inflammation and elevated number of alternatively
activated M2 macrophages observed in CD13 null grafts (Figure 3.6) can be
attributed to a degranulation-independent anti-inflammatory function of CD13 null
mast cells. To determine if CD13 null mast cells could be exerting their antiinflammatory role at least in part by skewing macrophage differentiation towards
the reparative M2 phenotype at the expense of a pro-inflammatory M1
phenotype, WT and CD13 null mast cells could be co-cultured with WT and CD13
null immature macrophages to determine mast cell mediated polarization of
macrophages towards either an M1 or M2 phenotype. Flow cytometric
comparison of CD11b+F4/80loLy6c+CD206- (for M1) and CD11b+F4/80hiLy6c/lo

CD206+ (for M2) would show differences in percentages if CD13 null mast cells

do indeed alter macrophage maturation. However, as our mast cell-dermal
fibroblast co-culture assays have shown, the absence of mast cell activation by
CD13 null dermal fibroblasts adds a layer of complexity that will have to be
addressed before definite conclusions can be drawn.

While our findings clearly show that absence of CD13 in donor cells or blockade
of CD13 in recipients is enough to promote long-term tolerance in miHC
mismatched grafts, they also indicate that exclusive manipulation of CD13 alone
is insufficient to promote acceptance against stronger immunogenic signals.
Thus, systematic analysis of CD13 blockade in conjunction with other targeted
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immunotherapies, such as CD200 activation or CTLA-4 Ig/PD-L1 overexpression,
must be executed to determine what combination provides optimal immuneregulation; one that supports graft survival without exposing patients to undue
harm [157, 158]. Development of such a donor-specific immune-modulatory
therapy will not only revolutionize transplant medicine, but also propel many
allogeneic stem cell-mediated therapies into clinical practice.

One natural corollary to this study is determining its applicability to human cells.
While we expect our overall observations to extend to human transplants, there is
marked species specificity in terms of CD13 antibody binding, which may imply
that the use of SL13 in humanized models may not reproduce the results
reported here. Thus, testing other known CD13 inhibitors such as bestatin, which
is already used in humans as a chemotherapeutic, or novel NGR motifassociated factors may provide alternative methods to generating de novo
monoclonal antibodies that block human CD13 [179, 180]. Derivation of human
pluripotent stem cells lacking CD13 may also provide a limitless source of donor
cells, but will first have to be assessed for universal acceptance in recipients with
intact immune systems, such as the humanized mice used in the CTLA-4Ig/PDL1 studies [157].
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Even after confirmation that CD13 blockade prevents human allograft rejection,
there are a number of hurtles to overcome. Efficient differentiation of pluripotent
stem cells and production of sufficient quantities of mature cells has been
difficult. For instance, a variety of methods for producing cells at different stages
of differentiation along the key cardiac and vascular lineages have been
developed. Directed differentiation protocols that involve co-culture with
endoderm or media containing certain cytokines like TGFβ, BMPs, and nitric
oxide (NO) have produced cardiac cells; however, the total yields have been
mediocre at only ~5% [39, 181-184]. The use of small molecules, like retinoic and
ascorbic acid, to aid in this process has also been unsatisfactory, most likely due
to the specific time window during differentiation where these molecules are
cardiogenic [185, 186]. The accumulation of protocols and inconsistent results
prompted Burridge et al. to try to streamline directed differentiation of cardiac
lineages. In a technical tour de force, they systematically assessed greater than
45 experimental variables that had previously been reported in the literature
[138]. Using both ESC and iPSC, they ultimately devised a 9-day protocol that
yielded beating embryoid bodies with 94.7% efficiency. While they did note a
slight difference in culture conditions for iPSC versus ESC, they showed that the
cardiomyocytes generated from either source were indistinguishable and
behaved like normal cardiomyocytes in terms of electrophysiology and response
to isoproterenol or pinacidil. The increasing movement to automate PSC
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production, maintenance and differentiation is also partially addressing current
technical limitations, but is still insufficient to meet the demand that would be
created by actual application of these cells in the clinic.

The timely manufacture of sufficient quantities of organ-specific cells is important;
however, every batch must be rigorously tested for safety since any residual
pluripotent stem cells could generate tumors. Early applications of pluripotent
stem cell-derived cardiomyocytes in animal studies have demonstrated the
horrible consequences of administering impure populations of cells [18, 187].
Thus, a standard and reproducible method of certifying the purity of the final cells
to be infused in human patients must be instituted. Many groups have
demonstrated that mES-derived cardiomyocytes successfully engrafted into
rodent hearts and improved contractility after myocardial infarction [188, 189];
however, hESC-derived cardiomyocytes that engraft and electrically coupled to
host myocardium may unfortunately give rise to ectopic pacemaking foci [19].
The development of new technologies to track transplanted cells in the living
body will permit continuous monitoring of donor cells over time for survival,
engraftment, and potential tumor formation [190]. Apart from simply determining
cell survival, evaluating therapeutic efficacy also requires the generation of new
surrogate endpoints as well as a shift in paradigm from short to longer term in
terms of the expected timing of measurable benefits to manifest. All of these
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issues are being actively addressed at the intersection of academia, industry,
government and medical institutions. In a globally unified effort, these individual
communities are interacting and collaboratively pursuing the realization of iPSCand ESC-based therapies, which are now finally transitioning to clinical trials.
These stem cell modalities assisted with immune-modulating therapies, such as
the one we propose here, could one day provide an off-the-shelf product that will
benefit any patient in need.
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